2.0 LPBI – 2021-2025 VISION

Our Logo

1.0 LPBI Group’s Team created

Ten Intellectual Property Asset Classes

https://pharmaceuticalintelligence.com/2019-vista/

All Contributors to Leaders in Pharmaceutical Business Intelligence (LPBI) Group

UPDATED on 9/17/2021

LPBI’s Opportunities Map

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

LPBI is seeking strategic avenues that are DIFFERENT than

Private Debt
Direct Public Offering

LPBI situation in 2021 is CLEAR

LPBI is Debt Free and needs to Sell Outright its Portfolio of Intellectual Property Assets:

1.0 LPBI IP Asset Classes I to X
2.0 LPBI IP Asset Classes to be created in 2021 – 2025 – Work-in-Progress on XI, XII, XIII, XIV

IP Asset Class XI – the outcomes of Missions #1 – NLP on Journal Articles, Books, E-Proceedings, Biological Images TextLegend IP Asset Class XII – the outcomes of Missions #3 – New Genre of Books: Spanish, Audio, NLP Results IP Asset Class XIII – the outcomes of Missions #4 – Drug Discovery with Synthetic Biology Software IP Asset Class XIV – the IT Infrastructure of a Blockchain Transactions Network – Missions #2. The Database Schema is the Ontology of the Journal and its Tags. For Search purposes the keywords extraction per article for Text Analysis with NLP in Mission #1 serves the query system as well.

Regarding Mission #2: Design of Blockchain Content Monetization Platform is in earnest on two fronts:

Internal: Erich and LMU CS Department using Fluree open source
External: Alliance with BurstIQ, Denver if deployment is needed in 3 months

Deep Learning NLP for Text Analysis: Journal articles (N=6,085), 18 e-Books, 100 e-Proceedings, +6,200 Biological Images with text legend

Internal: Wolfram Deep Learning NLP
External: Linguamatics/IQVIQ, if Scaling up from Proof-of-Concept to all Books called by a Joint Customer [Insurer in UT is Aviva’s Contact]

LPBI Team members understand that the following two strategies are not the appropriate strategies for us to undertake. These strategies are:

Private Debt

No person on LPBI’s Team would sign a LOAN and commit to pay it back. Even if we incorporate – the Team members will not take such a responsibility.

Direct Public Offering (DPO)

DPO – most likely is not suitable for any IP Portfolio. These asset classes, their value has a very strong INTANGIBLE component, they are Intellectual Property not Real estate or tangible assets. Thus, can’t be treated as securities. Therefore, LPBI’s Founder and Board are seeking an Acquirer that will

Acquire the assets
Incorporate the business and
Bring a new Team
In this scenario, the new business may be suitable for Private Debt ????
LPBI’s Team members are not suitable to raise debt

UPDATED on 8/31/2021

August 31, 2021 is a GREAT day for both organizations:

Montero, Language Services, Madrid for COMPLETION of the Spanish Translation of LPBI Group’s EIGHTEEN Books in Medicine: Books Page Cover and electronic Table of Contents (eTOCs) per Volume
LPBI Group, Boston for having the EIGHTEEN products of the Spanish Translation as agreed upon

This Spanish Translation serves our quest to

(1) have the opportunity to REACH to the Medical communities in Spanish speaking countries and to Spanish speaking physicians and allied health professionals in the US, and
(2) having the ability to re-Publish every book and every e-Series as a New Genre of Scientific Books in several new formats:

Series A, B, C, D, E – per each Series:

Never published before as eTOCs of all Volumes in a Series
Never published before in Spanish: Text or Audio
Never published before in English Audio

All volumes in each Series – Bi-Lingual and Audio eTOCs

Cover Page and electronic Table of Contents

Spanish & English Bi-Lingual eTOCs in Text – Today the FINAL products delivered
Spanish eTOCs Translation in Audio [Text to Sound]
English eTOCs in Audio [Text to Sound]

Per Volume for each of the 18 Books – New Genre of Scientific Books

Part A: Bi-Lingual eTOCs: Spanish Audio and English Audio
Part B: Results of Deep Learning Natural Language Processing with Domain Knowledge Expert Interpretation in [English text work-in-progress] and Spanish text to be translation of this English Text [Future Plan]
Part C: Book original Editorials in English Audio [Text to Sound]

UPDATED on 8/20/2021

2.0 LPBI all Products of NLP, see Yields for Mission #1 in:

2.0 LPBI is a Very Unique Organization

PLUS Pipeline Products, 2021-2025, 2.0 LPBI which include:

IP Asset Classes: XI

IP Asset Classes: XII

IP Asset Classes: XIII

IP Asset Classes: XIV

Beyond 1.0 Ten TEN IP Asset Classes are

2.0 LPBI IP Asset Class: XI, XII, XIII, XIV

IP Asset Class XI (Queries yielding results on the Fly) – ending up in Blockchain storage available for monetization as a new product

New Digital Products as a result of Discovery 💡 of new digital products derived from and created for the new queries by users to be generated on the fly not in existence in the knowledge graph database

In addition, all new Digital Products of Mission #3 and Mission #4

IP Asset Class XII (Mission #3) – ending up in Blockchain storage available for monetization transactions as new products

All digital products of Mission #3, below: New Genre of Scientific Books N =18, see book architecture, below,

IP Asset Class XIII (Mission #4) – ending up in Blockchain storage available for monetization transactions as new products

All digital products of Mission #4, below: New therapeutics molecules generated for 12 Galectins by Synthetic Biology software

IP Asset Class XIV (Mission #2) – is the Blockchain infrastructure

UPDATED on 8/4/2021 The SIX strategies in the UPDATED on 7/8/2021, below were condensed into four Missions, as follows:

Mission #1 is equivalent to Strategy #1: NLP
Mission #2 is equivalent to Strategy #2: Blockchain
Mission #3 is equivalent to Strategy #3: Book Translation to Spanish and other Foreign languages; Strategy #4: Podcast: Text to Sound and Strategy #6: AudioBooks
Mission #4 is equivalent to Strategy #5: Drug Discovery

Brief description of each mission follows, below:

Mission #1: NLP – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Statistical NLP and Deep Learning by Machine Learning using Wolfram Language for Biological Sciences

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

Mission #2: Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph Databases – Content monetization infrastructure B2B and B2C.

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

Mission #3: BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

Mission #4: Synthetic Biology Software: Drug discovery Galectins

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

UPDATED on 7/8/2021 RESULTS for 2.0 LPBI SIX Strategies, 2021-2025:

Strategy #1: NLP on existing 3.3 Giga Bytes of own content –>> ongoing – Proof-of-Concept presented on July 13, 2021 to a major health care insurer
Strategy #2: Blockchain for content monetization design –>> ongoing – two presentations on July 21, 2021
Strategy #3: Translation to Spanish for 22 Spanish speaking Countries: 18 Books Cover Page and electronic Table of Contents –>> 10 out of 18 completed
Strategy #4: Text to Audio conversion: Library of Podcasts under development –>> +280 podcasts library launch in 2021
Strategy #5: Synthetic Biology for Drug Discovery –>> Targeted as one mission for LPBI India launched on 7/19/2021
Strategy #6: e-Books to Audio Books –> Targeted for 2022

Details on the six 2.0 LPBI new strategies that represent the Pipelines for 2021 – 2025 include the following:

Strategy #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Strategy #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: a Partner has lined them up and are willing to build the Front End

To accomplish Strategy #1 and Strategy #2 – a bridge investment is needed for:

SCALING up NLP on four IP Asset Classes [Journal, Books, e-Proceeding, Biological Images], and
Finance the BLOCKCHAIN IT infrastructure development and DATA indexing and Migration for Content Monetization: Vendor’s Quote and monthly fees till the Exit
Finance the Content Promotion REQUIRED to generate transactions and the development of B2C opportunities
Finance marketing effort needed for the development of B2B opportunities in Pharma & Healthcare Insurance

Strategy #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

Strategy #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL

Strategy #5: Joint venture with Biotech Accelerator for Drug Discovery:

We worked together in 2015-2016 for 2 years – Plan for 2020-2021: Galectins explored as drug-able by Scientists using Synthetic Biology to design new drug molecules

INTERNS are joining after Labor Day – they need to gain some LAB Flavor in return for working as Volunteers @LPBI projects: SEE

2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates

2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP) 9/2020 – 9/2021

Strategy #6: e-Books Translations into Japanese, Spanish, Russian

Decision taken to Translate to Foreign languages only two artifacts: Cover Pages and electronic Table of COntents (eTOCs) and start with Spanish

UPDATED ON 6/17/2021 Stephen J. Williams, PhD, LPBI’s CSO is the Project LEAD for Medical Text Analysis using Machine Learning (ML) and Natural Language Processing (NLP)

Genomics contents – 2 volumes – Series B
Cancer contents – 2 volumes – Series C
Immunology-related contents – 4 volumes Series D

Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI (2012-2020) and 2.0 LPBI (2021-2025) serves as Project LEAD for Medical Text Analysis using Machine Learning (ML) and Natural Language Processing (NLP)

Cardiovascular contents – 6 volumes – Series A
Precision Medicien contents – 4 volumes – Series E

The Initiative Medical Text Analysis using Machine Learning (ML) and Natural Language Processing (NLP) is described in the following links https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/ And https://pharmaceuticalintelligence.com/vision/ And https://pharmaceuticalintelligence.com/blockchain-transactions-network/

We use Wolfram Language for Biological Sciences

Our First need is python code to be written for the NLP algorithms

Text Analysis The Wolfram Language

We wish to have several students in CS at UT, Arlington that are interested to work with LPBI on that Initiative
We wish to discuss our CS needs

We wish to generate the following visualization artifacts:

WordClouds – one per article – we use WordItOut.com – Output requires Editing – can that be automated??
Bar Diagrams of word frequencies per article and per all articles in a Chapter in a Book – Top 12, edited to eliminate words, I.e., some, only, the, and, or – can that be automated??
One Hyper-graph for all articles in one chapter in a book – representing the Semantics relations among concepts
One Tree Diagram for all articles in one chapter in a book – representing the affinity among clusters of concepts

Currently, we have code for all of the above that is unsatisfactory, yet

We have CODING needs to generate Visualization artifacts that we accept as Templates for scaling up the Production Process of visualization artifacts

We wish to automate the Editing process of eliminating words, I.e., some, only, the, and, or from 1 and 2, above
3 and 4, above display article ID instead of concepts
Tree Diagram needs scale adjustment and display of concepts vs article ID
Advise LPBI on additional features of NLP by Wolfram

THE SCALING PROCESS:

Production of visualization artifacts

Phase 1: Completed: A Pilot Study

Wolfram NLP on 33 articles and 20 Biological images – NLP by LPBI Team
Linguamatics NLP on SAME 33 articles and 20 Biological images – NLP by Linguamatics Team
RESULTS are presented on July 13, 2021 to a Client in UT via Zoom by the teams of 1.1 and 1.2, above

Phase 2: Scaling up to 4 books: Genomics, Volume 1 & 2 and Cancer, Volume 1 & 2, see URLs, below

Phase 3: Scaling up to ALL 18 Books

Phase 4: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

The Wolfram Solution for Biological Sciences
The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

LPBI Group’s FOUR Corpuses

All +6,000 Journal Articles
18 Books in Medicine ~2,000 articles from the +6,000 Journal articles https://lnkd.in/ekWGNqA
100 Documents: 60 e-Proceedings & 36 Tweet Collections of TOP Global Medical and Biotech Conferences, 2013 – 2021
5,200 Biological Images that have Text Legend

Scaling up involves additional TEXT ANALYSIS Tasks:

Two methods for Content Segmentation

Content Segmentation by other criteria for Narrow casting the content of the journal ontology, Categories of Research (N = 730). About 70% are related to Drug Discovery
Content Segmentation criterion: I.e., All articles in one Chapter in one Book

Phase 5: INDEXING all the 4 corpuses

Here we wish to engage CS student at UT, Arlington to develop our needs in INDEXING

All +6,000 Journal Articles MINUS the articles included in 18 Books ~2,000 articles
18 Books in Medicine ~2,000 articles
100 Documents: 60 e-Proceedings & 36 Tweet Collections of TOP Global Medical and Biotech Conferences, 2013 – 2021
5,200 Biological Images that have Text Legend

Phase 6: Jointly Migrate the Data to a Blockchain Transactions Network – See image, below

We are inclined to engage in INDEXING without involvement of 3^rd party but with UT, Arlington CS Students
We are inclined to engage in NLP using Wolfram License for use in API of the Blockchain vs other NLP vendors

List of Books in Phase #2:

Series C: e-Books on Cancer & Oncology

Volume 1:

Cancer Biology and Genomics for Disease Diagnosis

http://www.amazon.com/dp/B013RVYR2K

Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

http://www.amazon.com/dp/B071VQ6YYK

and

Series B: Frontiers in Genomics Research

Volume 1:

Genomics Orientations for Personalized Medicine

http://www.amazon.com/dp/B018DHBUO6

Volume 2:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

UPDATED ON 6/7/2021

LPBI is planning CREATE A NEW WEBSITE for All the Content in our BioMed Tab on our Website for the SPANISH TRANSLATION

We will CREATE A NEW WEBSITE for All the Content in our BioMed Tab on our Website

https://pharmaceuticalintelligence.com/biomed-e-books/

The BioMed e-Series SPANISH Website will have SIX pages

Page #1: eTOCs for all Volumes in Series A

Nested links:

eTOCs of Volume 1

eTOCs of Volume 2

eTOCs of Volume 3

eTOCs of Volume 4

eTOCs of Volume 5

eTOCs of Volume 6

Page #2: eTOCs for all Volumes in Series B

Nested links:

eTOCs of Volume 1

eTOCs of Volume 2

Page #3: eTOCs for all Volumes in Series C

Nested links:

eTOCs of Volume 1

eTOCs of Volume 2

Page #4: eTOCs for all Volumes in Series D

Nested links:

eTOCs of Volume 1

eTOCs of Volume 2

eTOCs of Volume 3

eTOCs of Volume 4

Page #5: eTOCs for all Volumes in Series E

Nested links:

eTOCs of Volume 1

eTOCs of Volume 2

eTOCs of Volume 3

eTOCs of Volume 4

Page #6: BioMed Tab on our Website – ENGLISH EDITION

https://pharmaceuticalintelligence.com/biomed-e-books/

QUESTIONS – Polling your views

1. This website will be stand alone IF AND ONLY IF

1.1 All articles included in the 18 books will be on that Website

1.2 Views will be recorded for this Website

2. For the Blockchain powered 2.0 LPBI’s Digital Store:

2.1 This Spanish Website will be a Shelf in the store with Accounting LEDGER of its own Monetization of the Spanish Translation

2.2 Expenses for Content promotion in Spanish and in Spanish speaking Countries

2.3 Will it have access to NLP Visualization done in English?

UPDATED ON 5/5/52021

One Pager for 2.0 LPBI Group

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 18 books have been downloaded ~135,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
From Open Access we will transition to Blockchain transaction networks.
From Digital Cloud-based biographies we will create audio and video Podcasts
From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships

Our Transformational transition is two dimensional:

Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia. Currently the Table of Contents of 18 books is being translated into Spanish for the 22 Countries speaking Spanish.
Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.

We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/

UPDATED ON 4/25/2021

Joint Marketing Campaign

LPBI Group & Montero, Language Services for

Spanish Edition

of LPBI Group’s BioMed e-Series

18 Books in Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/

All books are available for Sale and Page Downloads on Amazon.com

https://lnkd.in/ekWGNqA

Advantages of a Joint Marketing Campaign
The Context:
The Competitive Landscape – covered in 1.0 LPBI Prospectus
1.0 LPBI Products versus 2.0 LPBI Products
The Benefits of Text Analysis Performed by Machine Learning
The Suite of Products – A Portfolio of Intellectual Properties (IP)
The Process of Content Purchase and Monetization
The Objective: Content Monetization and Global Dissemination of Life Sciences Innovations
The Content is Offered to the Content Consumer: B2B and B2C
List of IP Assets – DIGITAL PUBLISHED PRODUCTS for Technology Transfer of Ownership
Content Availability by Access Mode
Marketing Communication Needs: 1 – 7
The Targets: END-USERS
Geographical Markets
Business Model for Blockchain Platform: Product Price List Itemized for 1.0 LPBI & 2.0 LPBI
For Venture Valuation Purposes: Statement #1, #2, #3, #4, #5, #6

Advantages of a Joint Marketing Campaign

LPBI does not have infrastructure in 22 Spanish speaking countries– 19 Countries is a more realistic number
LPBI needs content promotion for the Spanish Edition done in Spanish by a local company with market familiarity in Latin America and Spain.
Montero, LS was given an opportunity for a significant Trans-Atlantic project allowing the demonstration of expertise and capacity to handle 18 books in Medicine. These books are of average length 2,400 pages. The longest book is 3,400 pages and shortest is ~1,000 pages. The electronic Table of Contents (eTOCs) comprises live links to the original articles in the journal, allowing the Spanish reader to electronically access the original articles
The Spanish Edition will be published for each book separately and there will be one collection of ALL 18 eTOCs – all in Spanish.
0 LPBI is creating interpretation of visual artifacts generated by Text Analysis and Test Mining using AI/ML/NLP. These interpretation text pages will be translated into Spanish, Japanese and Russian.
0 LPBI’s new content could present a follow up project for Montero, LS.

The Context:

Montero’s partner, known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, HQS in Boston, MA, USA is planning the launch of its Digital Store in a Healthcare Digital Marketplace designed and operated by BurstIQ. The Digital Store is using a Blockchain Transactions Network as its IT platform for B2C and B2B transactions for their digital content. The available digital content in Life Sciences, Pharmaceutical, Healthcare, Medicine, Medical Devices, Medical equipment, Biotech and Bioscience includes the 1.0 LPBI IP Portfolio of an e-Scientific Publisher – 3.3 Giga bytes of English text and Biological images. The portfolio contains four IP asset classes:

6,000 scientific Journal articles – curations of peer reviewed scientific findings – with clinical interpretation written by experts.
18 Books in Medicine and Pharmaceutics
100 e-Proceedings of the most important Medical and Biotech Global Conferences that we covered in real time using PRESS passes and Tweet Collections from 36 events
5,100 Biological images used in the articles mentioned above

The Blockchain design of the IT platform for Content Transactions will include, in addition to the 1.0 LPBI IP Portfolio (2012-2020) described above (the four IP asset classes), the 2.0 LPBI IP Portfolio of visualization artifacts currently under development.

2.0 LPBI IP Portfolio (2021-2025) consists of expert Interpretation of the visualization products resulting from Medical Text Analysis and Text Mining of all its Digital Published Products. The Text Analysis and Text Mining is performed by advanced algorithms from Artificial Intelligence (AI), Machine Learning (ML) and Natural Language Processing (NLP).

Montero is currently translating from English into Spanish the cover pages and the electronic Table of Contents of 18 Books in Medicine and Pharmaceutics
This project originator is Dr. Aviva Lev-Ari, PhD, RN, who is the Founder of 1.0 LPBI and 2.0 LPBI and Editor-in-Chief of the Journal [com] and of the BioMed e-Series [https://lnkd.in/ekWGNqA]

In 2021 LPBI Group began the transition from:

A nine years young profile of being

A very dynamic and cutting age electronic Scientific Publisher,

Known as 1.0 LPBI during 2012 – 2020 toward designing its new image while becoming a new Company with a new profile, Known as 2.0 LPBI in 2021, for 2021 – 2025

A Medical Text Analysis company using (NLP-ML-AI) – Software as a Service (SaaS) and
Content Monetization (on a Blockchain Transactions Network) – Blockchain as a Service (BaaS).

The Blockchain platform design includes the following five features:

Recommendation Engine residing on a blockchain
Permissions,
Immutable LEDGER,
Smart contracts and
Cyber-security for protecting the IP

Economies of scale will be achieved by:

Development of one content promotion system
Unified IT cloud-based infrastructure
Maintenance of B2C IT transaction system in a Digital Store at a Healthcare Marketplace [monthly fee paid for the use of the network and
Installations of B2B Point-of-Research (PORs) at institution – pay per use vs subscription base – type of contracts not specified yet.

The Competitive Landscape

2.0 LPBI is a Very Unique Organization

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/ The uniqueness and the competitive space is addressed at length in 1.0 LPBI Prospectus, a 300 page document

It Is sent as an attachment separately
List of competitors using Blockchain are telemedicine companies not scientific e-publishers

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

NO other e-Scientific Publisher is Using NLP on a Blockchain platform.
LPBI has the FIRST MOVER ADVANTAGE over all other e-Scientific Publishers
LPBI had the FIRST MOVER ADVANTAGE in curation of scientific findings in 2012.
Our NLP Partner, Linguamatics said: No client ever asked us about Blockchain
Our Blockchain IT Partner, BurstIQ said: No client ever asked us about NLP
LPBI is now working with both on an entirely solution.
All the Text Analysis with NLP currently done covers the Literature in the Public Domain: PubMed, MedLine, other Ontologies and Formularies
Peer reviewed articles in PubMed, MedLine publish content only on EXPERIMENTS and on Clinical Trials
LPBI content is CURATIONS by Experts, secondary research on the clinical interpretation of primary research using ONLY peer reviewed published articles as sources.

1.0 LPBI Products versus 2.0 LPBI Products

A. 1.0 LPBI – Blockchain LEDGER for Content Monetization of IP Asset Classes I, II, III, V LPBI 1.0, 2012-2020 is the creator and the custodian of the Portfolio of ten IP Assets Classes. For content monetization, we identified four of the ten assets that are related to the curation methodology and process: Class I: Journal articles, Class II: 18 Books, Class III: 100 e-Proceedings & Tweet Collections, Class V: +5,100 Biological Images The Use Case for data entity design and meta data architecture is a Journal article. It has the following Profile:

Article ID – IP Asset Class I
Author
URL
Date of Publication
Research Categories assigned by Author(s)
Is this Article a Curation or a Scientific Report
Is this Article included in a Book? If yes, in which Books – IP Asset Class II
Is this Article a component of an e-Proceedings? If Yes, What is the Conference Title, Date, Location – IP Asset Class III
List of Biological Images included in this article – IP Asset Class V

B. 2.0 LPBI Digital Products: ALL the content of 3.3 Giga Bytes is to be subjected to Text Analysis with AI/ML/NLP. The Products of this Machine Learning analysis of text are in the format of visualization artifacts (Graph Files). They represent the SEMANTIC relationships between concepts and keywords ACROSS all articles in One Chapter of the book or in several main Categories of Research.

This aggregation of content, i.e., 20 articles making up a Chapter in a book or 20 articles were all written by different authors/curators, yet all have been assigned the same research categories. This means that semantically these two collections of articles represent a common theme or similar location on the Tree of knowledge, represented be spatial proximity to a similarity graph (Hyper-graph) or on an hierarchical clustering graph (Tree Diagram).

The Benefits of Text Analysis performed by Machine Learning Algorithms

All articles are in one Chapter in the book
Some Articles in several main Categories of Research are assigned to the article by the Author/Curator
Some research categories have +1,000 articles assigned, i.e., Cancer Biology & Therapies

These attributes: Assignment of an article a Chapter in a book or a research category represent the thematic context of the article. The context reveals INSIGHTS needed for understanding relationships among articles vs each of the 6,000 articles to stand alone as a singular point in knowledge space. Thus these two affiliation criteria serve as classifiers. LPBI’s Journal has an ontology of 670 categories of research. In theory one could run NLP on all the articles in each of these 670 categories and reach a semantic map for the entire universe of the Journal Corpus. Current offering from LPBI are four corpuses, Text Analysis with NLP done by Machine Learning software is the ENGINE for identification of conceptual relationship in context.

The Suite of Products – A Portfolio of Intellectual Properties (IP):

Four Corpuses in details:

6,000 scientific Journal articles – curations of peer reviewed scientific findings – with clinical interpretation written by experts.
18 Books in Medicine and Pharmaceutics
100 e-Proceedings of the most important Medical and Biotech Global Conferences covered in real time on PRESS passes and Tweet Collections from 36 events
5,100 Biological images used in the articles above

The Journal consists of

Posts (6,037 on 4/23/2021),
Pages (393 on 4/23/2021)

Posts consist of four Article Types:

Type A: Authored article by an Expert, Author, Writer (EAW) or more then one – all are PhD, MD, MD/PhD, PharmD level
Type B: Curated article by an EAW or more then one – all are PhD, MD, MD/PhD, PharmD level
Type C: Scientific Reports by an EAW, by a PostDoc level or by a Masters Level
Type D: e-Proceedings of Conferences and Tweet Collections. Namely, all e-Proceedings are Posts not Pages

Pages consist of three Page Types

Public Published Page
Password Protected Page
Public Published Page that is a Book

Example of Recently Published Posts, Live links

Apr 19th, 10:22 AM Identification of novel genes in humans that fight COVID-19 infection
Apr 14th, 4:42 PM The top 10 medtech M&A deals of 2020
Apr 14th, 12:56 PM Mechanism of Thrombosis with AstraZeneca and J & J Vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD
Apr 13th, 3:37 PM Fighting chaos with care, community trust, engagement must be cornerstones of pandemic response
Apr 12th, 3:34 PM Linking Thrombotic Thrombocytopenia to ChAdOx1 nCov-19 Vaccination, AstraZeneca

18 Books in Medicine and Pharmaceutics

The BioMed e-Series, 18 volumes consist of five multi volume series.

BioMed e-Series

Series A: e-Books on Cardiovascular Diseases – Six volumes
Series B: Frontiers in Genomics Research – Two volumes
Series C: e-Books on Cancer & Oncology – Two volumes
Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases and Genomic Endocrinology – Four volumes
Series E: Patient-Centered Medicine – Four volumes

The majority of the articles in these books are CURATIONS
Curation of Scientific Findings is a unique methodology for creation of Posts which are Journal articles. It is explained in Chapter 1 in Series A, Volume 2

Cardiovascular Diseases, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation. On Amazon.com since 11/30/2015

http://www.amazon.com/dp/B018Q5MCN8

These 18 Books consist of application of the Curation Methodology for the creation of electronic Table of Contents (eTOCs) for each of the 18 books
This Methodology allowed our Expert Editors to produce systematic classification of all eTOCs by culling articles from the journals’ research categories to create a one of a kind eTOCs for each volume
Lev-Ari was involved in the creation of 14 of the eTOCS of the BioMed e-Series books
Except for Series B, Volume 1 (Dr. Williams & 3 Editors); Series D, Volume 1 and Series E, Volume 2 & 3 (Single Author/Editor, Dr. LHB)

In 2021, 2.0 LPBI is planning to launch a Blockchain Transactions Network Ecosystem to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections and Biological Images

Regarding Selling books and the Blockchain IT Platform:

The current plan is to promote the books and refer the interested Content Consumer/End-User to purchase the Books on Amazon.com which grants 35% of books Sales to Authors. Amazon.com does not allow selling the book on any other platform, per contract signed by authors under KDP. However, the Transfer of Ownership of the LPBI IP Portfolio can include a condition for removal of the Books from the Amazon.com platform, Kindle Sore and the permission to republish the book under a New Publisher Title, keeping all contents and authors as currently listed on the Amazon platform. Under that condition, a book priced $135 may remain at the same price or the price may change; in either case 100% of the Price upon a book sale will be recorded and credited by the new Publisher. This scenario may be favorable to a Scientific publisher with a Global distribution of Books infrastructure in place.

The Process of Content Purchase and Monetization – How will it work on the Blockchain Transactions Network?

The content will be downloaded into a Digital Cart subsequent to Content Customer conducting a query to interrogate the Knowledge repositories of our four corpuses stored on a Blockchain IT infrastructure, which represents the back-end of a Digital Store and executes the data and transaction processing functionality on the Healthcare Digital Marketplace
The Recommendation Engines (one for Text), one for Biological Images) presents the Content Customer with selection choices and a Price Tag associated with all selection options
Content Customer performs selections on a FORM after reviewing all recommendations – The Front-end of the transaction GUI.
Form submission generates an Invoice
Invoice is Paid
Permission is authorized by the blockchain system
All content selected is downloaded in Content Customer’s cart and becomes available for use instantaneously
On the back-end, the transaction is recorded on the LEDGER and funds are transferred from the Content Consumer to LPBI Account Receivable

Content Customer/End-user interact with a computer screen or a mobile device for submission of queries to DBs in the Digital Store:

Options for selection include:

Knowledge repositories [1.0 LPBI IP Asset Classes I, II, III, V]: Content Customer/End-user will submit a query and will Specify

Current, Choices for the search:

I. Original articles,
II. Books,
III. e-Proceedings and Tweet Collections and
V. Biological Images or
All of the above

The current choices for the search are NOW in Read Only mode since the content in the WordPress.com Cloud is not connected to a Transactions Network.

We design the Blockchain and the digital store to enable transactions for our current and future digital content.

LPBI’s new Content will continue to be added to the WordPress.com Cloud and migrated to the Blockchain system This process has not yet been specified since the indexing and the current content migration of 3.3 Giga Bytes has not yet started. The Blockchain is under DESIGN. BETA testing, Launch will follow Work-in-Progress – Future Digital Products for Content Customer/End-user to specify during interaction with the System

Spanish Translated eTOCs of 18 Books [Montero current involvement]

Work-in-Progress – Customer/End-user to specify during interaction with the Text Analysis by AI/ML/NLP

Specifying Visualization artifacts generated by AI/ML/NLP as a result of Text Analysis and Text Mining
Specifying the Foreign Language for the Interpretation of Visualization: Spanish, Japanese, Russian [Montero potential future involvement]

The Objective: Content Monetization & Global Dissemination of Life Sciences Scientific Innovations

The transformative work done by LPBI Group allows cutting-edge biomedical research innovation to be widely disseminated and accessible to the global research and non-research communities The Blockchain Transactions Network enables Selling Content on the INTERNET to B2C and to B2B

LPBI’s method of curation represents a mode of scientific communication including synthesis, analysis, and interpretation done by experts in +6,000 Journal Posts and ~400 Pages
Experts, authors, and writers add their knowledge and expertise in re-thinking and conceptualizing subjects selected in their domain of expertise, to form new curations and update existing ones.
The books are transformative in their capacity to accelerate diffusion of scientific innovations. They represent the frontier of life sciences research.
The curation is done by experts with a perspective within each field, allowing for the creation of scientific content that combines conceptual evolution within the scientific breakthroughs analyzed together with their anticipated future implications.

The Content is offered to the Content Consumer – B2B and B2C:

LPBI content is in Life Sciences, Pharmaceutical, Healthcare, Medicine, Medical Devices. Thus, it would attract institutions active in several verticals 1.0 LPBI IP Portfolio of an e-Scientific Publisher

A. Present 3.3 Giga bytes of English text and Biological Images

Intellectual property of LPBI is of four types: A corpus of curated articles,

6,000 scientific Journal articles – curations of peer reviewed scientific findings – the clinical interpretation written by experts.

A corpus of e-books

18 Books in Medicine and Pharmaceutics

A corpus of e-proceedings

100 e-Proceedings of the most important Medical and Biotech Global Conferences covered in real time using PRESS passes and Tweet Collections from 36 events

A Gallery of Biological Images

5,100 Biological images used in the articles above

B. Future 2.0 LPBI Suite of Visualization Artifacts created by Text Analysis with AI/ML/NLP

Will be available on the Blockchain platform and will be produced on the fly per distinct queries submitted by the Content Consumer to the Content Databases: Visualization artifacts produced by AI/ML/NLP include the following files: As scaling up takes place, these artifacts will become available for download and monetized at a

per Article basis in the +6,000 corpus
Collections of articles in Books’ chapters
Main research categories assigned to articles by authors/curators
On demand, collections specified by end-users produced on the fly on the Blockchain platform enriched with Data Science & Analytics features [some are currently done in the NLP environment; more can be done on the Blockchain when all the four corpuses become live for transactions and for Analytics]

List of New digital products to be produced by LPBI Team working on

Medical Text Analysis using NLP strategy:

Graph Files

WordClouds representing Article abstracts
Bar Diagrams representing Word Frequencies
Hyper-graphs representing Semantic relationships
Tree Diagrams representing hierarchical clustering of conceptual similarities

Text Files Interpretations of the visualization artifacts generated by AI/ML/NLP are included in the plan Multi-Lingual Translation of the Text Files produced by Domain Knowledge Experts.

Spanish
Japanese
Russian

The Volume of Content Consumed to date:

Books published on Amazon.com – To date: +135,000 pages have been downloaded from the 18 Volumes.
Journal articles (Posts and Pages): To date: ~2MM Views
We used data on Actual Article Views since date of publication (2012-2020) for projection of Article Views (2021-2025)
Assumption: One view is a download of a $30 article
Projection of Revenues: 2021-2025 based on actual ~2MM views, 2012-2020

PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views

https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/ See explanations in 1.0 LPBI Prospectus

Content Availability by Access Mode

Read Only

Present – All content Is hosted on

https://pharmaceuticalintelligence.com/

2021 – New Website is under construction
New URL for 2.0 LPBI, Medical Text Analysis with AI/ML/NLP and Blockchain for Content Monetization
See two alternative Site Maps for new website design – Work-in-Progress

https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/

Transactions enabled Website

for Books on Amazon.com – Kindle Store, Bookshelf: Life Sciences & Medicine – 18 Books in Medicine & Pharmaceutics

https://lnkd.in/ekWGNqA

LPBI Digital Store in Healthcare Marketplace – Ecosystem for content downloads and content monetization – Transactions enabled interface

Design of Blockchain IT Transactions Network – Work-in-Progress

Marketing Communication Needs: 1 – 7

Spanish Edition – Content promotion of 18 Medical books in Spanish speaking Countries
LPBI has needs in Marketing Communication, Media & PR for the venture’s potential M&A by a 3^rd party: i.e., Scientific Publisher, Healthcare NGO, Ministry of Education in Country x,y,z, Research Institute, i.e., National Institute of Health in Country x,y,z
0 LPBI is producing new digital media: Priority #1: Audio Podcasts. Future plans under new ownership: Audio Articles, Audio Books,
0 LPBI is producing new Visualization artifacts as outcomes of Text Analysis with AI/ML/NLP
0 LPBI is Planning Advertisement for Amazon Books using Amazon Advertising in different countries for different book volumes, i.e., Genomics Volume 2 in the UK, Cancer Volume 1 & 2 in Latin America – This is a case of promotion of Books – expertise in auctions used in experimental design of advertisement running Ads is needed.
NEW documentation on IT Architecture for Content Monetization of Journal articles on the Blockchain IT infrastructure – Work-in-Progress
NEW documentation for content promotion and Monetization of other IP Asset Classes: Biological Images, e-Proceedings – Work-in-Progress

The Targets: END-USERS are the Life Sciences Content Consumers: including physicians, biotech knowledge worker, big pharma R&D and Medical Affairs Departments, Investment community in Healthcare

MedCity SPOTLIGHT Video – Healthcare Trends and Venture Capital Outlook

https://www.youtube.com/watch?v=YEfNWan0l5Q

A. For the Spanish Edition of 18 Books in Medicine

B2B

Tier 1: Scientific Publishers

Medical Education – University Libraries
Online Education Institutions
CRO & CRA

Tier 2: Big Pharma & Diagnostics

Medical and Pharma Associations
Information Syndicators

Tier 3: Global Biotech & Pharmaceutical Conference Organizer

B2C

Tier 1: College students

R&D Departments in Public Health and Medical Research Institutes
Government Research organization: the equivalent to NIH, NCI, NSF

B. For Transfer of Ownership (TofO) of the IP Portfolio

Potential Acquirers in Five Economic Sectors and Industries:

Financial Sector,
Information Technology (IT) Companies,
Manufacturing,
Education: Private & Public Institutions
Media Syndicators

Prospects for Transfer of Ownership Tier 1:

Holding Companies, Investment Bankers and Private Equity
Information Technology Companies – Health Care
CRO & CRA
Information Syndicators

Tier 2:

Scientific Publishers
Big Pharma
Internet Health Care Media & Digital Health
Medical and Pharma Associations

Tier 3:

Online Education
Health Insurance Companies & HMOs
Medical Education
Global Biotech & Pharmaceutical Conference Organizer

Geographical Markets

A. For the Spanish Edition of 18 Books in Medicine Tier 1: Latin America Tier 2: Spain & Philippine

Argentina – Tier 1
Bolivia
Chile – Tier 1
Colombia
Costa Rica
Cuba
Dominican Republic
Ecuador
El Salvador
Guatemala
Haiti
Honduras
Mexico – Tier 1
Nicaragua
Panama
Paraguay
Peru
Uruguay
Venezuela

B. For the Transfer of Ownership of the IP Ten Asset Classes – Global Scope

Business Model for Blockchain Platform:

Product Price List Itemized for 1.0 LPBI & 2.0 LPBI

B2B & B2C will access 1.0 LPBI & 2.0 LPBI Products

Price List below represents B2C

Market installations in B2B will have a different Pricing structure based on Point-of-Research (POR)

1.0 LPBI – Digital Products
2.0 LPBI – Visualization (Graphical) Products & Multi-Lingual Interpretations

Product Price List Itemized for 1.0 LPBI Digital Published Products

One Article Download $30
Book Purchase on Amazon.com

https://lnkd.in/ekWGNqA

(1) Price List of Books (Price range $75 to $135 per book, Six volumes on Cardiovascular bundled for $515 (2) Page per View

Book Page Download on Amazon.com – Price determined by Amazon.com

TO BE AVAILABLE for downloud and purchase on Blockchain

Downloads of 1.0 LPBI’s Digital Printed Products on 2.0 LPBI Infrastructure

One eProceedings or One Tweet Collections $100
One Biological Image $30
Spanish eTOCs – One volume $15
Spanish eTOCs all 18 Volume $125

Product Price List Itemized for 2.0 LPBI Visualization Artifacts produced by

AI/ML/NLP & Interpretation Text Products

A PowerPoint Presentation based on a Proof-of-Concept of 33 articles in Cancer, including examples for each Visualization Artifact is available. Currently, these products are not YET available for sale – to download digital content following payment requires a BLOCKCHAIN platform with the features mentioned above – it is under design – Work-in-Progress

WordClouds representing Article abstracts $20
Bar Diagrams representing Word Frequencies $20
Hyper-graphs representing Semantic relationships $20
Tree Diagrams representing hierarchical clustering of conceptual similarities $20
Interpretation of Visualization Artifacts

English $20 Spanish $30 Japanese $30 Russian $30

STRATEGIC IMPLEMENTATION

It is LPBI’s founder’s quest to explore new business opportunities stemming from

(a) Attainment of significant milestones by development of 1.0 LPBI’s IP Portfolio, which can have a life of its own (b) New Management needed for talent acquisition to lead 2.0 LPBI’s new technologies (c) Building the staff with the skills needed for 2.0 LPBI, which differ from the set of skills prevalent at an e-Scientific Publisher (d) Bridge Investment needed involved in

Phase I: Transformation and Transition required for the following projects:

Global content promotion using Amazon Advertising that provides Analytics on $ spent and sales gained
Marketing Communication projects
Blockchain infrastructure design and implementation
Data indexing and data migration to blockchain platform: +6,000articles and ~400 pages
Scaling up the NLP phase to 3.3 Gigabytes of data
Translations to Foreign languages: Spanish, Japanese, Russian
Decisions on Audio articles and Audio Books and estimating the cost involved
Management of the Digital Store Shelves and subletting shelves to cover the monthly fees of network usage beyond the Network management provided with the monthly fee by the host of the Digital Marketplace
Subletting shelves in the Digital Store to cover the monthly fees of network usagewould require Recruitment of Content Creators to host and transact their content in LPBI’s Digital Store.
Enabling a content marketplace for 3^rdparty content creators to contribute and monetize their own content (was discussed as a future phase after the foundational marketplace is created using LPBI content).

Phase II: Pursuit of Conceptualization for the pipelines leading to the transition to 2.0 LPBI.

Phase II is paving the way to

A new organization
Need for new ownership
Need for new management

Phase III: Preparing for Phase 2: M&A and Exit.

See Elevator Pitches by all team members:

Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words

https://pharmaceuticalintelligence.com/2020/10/20/versions-of-lpbi-groups-elevator-pitch-2-0-lpbi-groups-team-in-our-own-words/ In light of Phase I, II, III, LPBI Founder is fully engaged and is running in parallel three strategic courses

The transition plan and new technologies emergence: NLP and Blockchain
Recruitment of External Business Relation, External Scientific Business relations, NLP team members, New Domain knowledge experts
The prospecting process in the event of Technology Transfer of Ownership: M&A talent

List of IP Assets for Technology Transfer of Ownership – DIGITAL PUBLISHED PRODUCTS:

IP Asset Class I: The Journal +6,000 Scientific articles https://lnkd.in/erfbayJ
IP Asset Class II: 18 Volumes in BioMed e-Series https://lnkd.in/ekWGNqA
IP Asset Class III: +100 eProceedings of BioTech & Medical Conference and Tweet Collections

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

IP Asset Class V: A Gallery of 5,100 Biological Images

https://pharmaceuticalintelligence.com/ See below considerations for Venture Valuation addressing IP Asset Classes: IV, VI, VII, VIII, IX, X, which are NOT related to the curation methodology

For Venture Valuation Purposes: Statement #1, #2, #3, #4, #5, #6

1.0 LPBI – Inventory of Digital Products

A VAST portfolio of IP developed by 1.0 LPBI since inception 2012-2020

+6,000 articles and 5,100 biological images,
18 books in Medicine
100 e-Proceedings & Tweet Collections
+3.3 Giga Bytes of IP
Translation of 18 books in Medicine: Title page and electronic Table of Contents to Spanish for 22 Counties speaking Spanish

2.0 LPBI – Technology and Marketing Strategies

2021-2025

Working with BurstIQ, a leader in Blockchain, on architecture of a platform for LPBI’s Content Monetization

A Store on BurstIQ HealthCare Digital Marketplace
Features of the Blockchain
Transactions Network: Recommendation Engine, Permissions, Smart Contracts, Immutable LEDGER, CyberSecurity, Content Promotions
We co-design the architecture to include NLP features to compute on Demand visualization artifacts

Working with Linguamatics/IQVIA on NLP scaling up from a Proof-of-concept to +6,000 articles, all books all e-Proceedings and Tweet collections and Biological images

Will get a quote for Licensing Linguamatics NLP Platform to LPBI
Or Licensing Linguamatics NLP Platform to BurstIQ

Working with Montero LS, Madrid, Spain on a Marketing Campaign for the SPANISH Edition resulting from translation of 18 books in Medicine: Title page and electronic Table of Contents to SPANISH for 22 Counties speaking Spanish

BioMed e-Series: 18 Volumes – electronic Table of Contents (eTOCs) of each Volume

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/

Accepted a quote for the translation job [Translation of 18 books in Medicine: Title page and electronic Table of Contents to SPANISH for 22 Counties speaking Spanish]
Will review a quote for the joint Marketing Campaign for Latin America with a focus on Mexico, Spain, Argentina
Will review a quote for Marketing Communications projects

FINANCIALS

LPBI Group is Debt Free

Was financed by the Founder, while
All the contributions of the Experts, Authors, Writers was performed on an Equity Sharingbasis
Sole source of income is represented by royalties paymentsevery 90 days by Amazon.com for page downloads and book sales

Summary – What are LPBI Group’s offerings?

These six statements, Statement #1, #2, #3, #4, #5, #6 are LPBI Group’s official view on its IP Portfolio for venture valuation purposes

Statement #1:

LPBI produced an unmatched volume of content created by experts, +3.3 Giga Bytes in TEN Intellectual Property (IP) Asset Classes.

https://pharmaceuticalintelligence.com/2019-vista/ Statement #2: This volume of content includes four distinct IP asset classes related to curation as a value added secondary research type, out of Ten IP Asset Classes.

Under Licensing agreements of LPBI’s Intellectual Property:
Each of these asset classes can become available to a mutually exclusive potential acquirer in the 12 economic segments listed on LPBI’s Opportunities Map.

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/ These are the four Curation-related IP Asset Classes:

IP Asset Class I: Journal articles, +6,000
IP Asset Class II: 18 Books in Medicine
IP Asset Class III: +100 e-Proceedings and Tweet Collections
IP Asset Class V: +5,100 Biological Images in Media Gallery

Statement #3: For some acquirers, IP Asset Classes NOT related to curation might be even MORE valuable than IP Asset Class I, II, III, V IP Asset Classes created by the curation methodology. IP Asset classes that are not related to Curation as a value added secondary research type include the following six:

IP Asset Class IV [composition of methods & platforms]
IP Asset Class VI [Team of Experts – Human Capital]
IP Asset Class VII [Royalties on IP paid by global customers]
IP Asset Class VIII [Website subscribers]
IP Asset Class IX [Intangible Assets: e-Reputation on Social Media by Institutional followings, Testimonials, “Influencer” rankings, 2MM Views of the Website, +500,000 views of LPBI’s Founder, Nominations, Book Page downloads +135,000]
IP Asset Class X [Podcast Library] +250 Podcasts on Interviews with Scientific Leadersexist in Text – will be converted into Audio PODCASTS, Work-in-Progress]

Request access privilege by Contact Us on the website PharmaceuticalIntelligence.com Statement #4: Linguamatics/IQVIA brought to the TABLE on 4/15/2021 their NLP platform developed in the last 20 years by co-Founder David Milward, PhD, CS, NLP.

Since 2020, they have used BERT technology [originated at Google] for Deep Learning in their established NLP environment for context analysis in text mining
Linguamatics/IQVIA is at the Top of the Top Tier NLP Players
Linguamatics based their Text Analysis of LPBI’s 33 articles and 20 Biological Images on three types of relations:

Genes – Diseases
Diseases – Drugs
Genes – Drugs

They enriched the content context by accessing Ontologies in Public Domain – a routine task in NLP
The Text Analysis with NLP on LPBI’s expert written curations will become a strong offering.

If in 33 [21+12] articles given to them by LPBI, Linguamatics Team had identified 673 relations

Genes – Diseases
Diseases – Drugs
Genes – Drugs

THEN

In LPBI’s +6,000 articles, Linguamatics’ NLP system would identify +120,000 relations

ALL Pharma and ALL Healthcare Insurers – ARE NOT AWARE OF +120,000 RELATIONS that machine learning algorithms are yet to unveil by NLP on LPBI’s produced and owned Content Statement #5: NLP for Medical Text Analysis and Blockchain Transactions Network for content monetization are significant technologies for LPBI’s venture valuation purposes Statement #6: LPBI’s content on Artificial Intelligence in Medicine was created in earnest for Genomics Volume 2. Respectively,

1.0 LPBI has domain knowledge on Artificial Intelligence in Medicine
2.0 LPBI’s focus is NLP for Medical Text Analysis rather than the BIG field of AI in Medicine

Regarding Artificial Intelligence in Medicine

LPBI has two PORTALS on AI:

AI in Genomics and Cancer

https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/

2021 Medical Text Analysis (NLP)

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/ In 2019, we published Series B, Volume 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

Part 3: AI in Medicine is in an LPBI’s Book

Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology ADDITIONAL SOURCES

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL. Author and Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/thriving-at-the-survival-calls-during-careers-in-the-digital-age-an-age-like-no-other-also-known-as-digital/

Pioneering implementation of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

UPDATED on 4/22/2021

For venture valuation purposes: Statement #1, #2, #3, #4, #5, #6

1.0 LPBI – Inventory of Digital Products – a VAST portfolio of IP developed by 1.0 LPBI since inception

2012-2020

+6,000 articles and 5,100 biological images,
18 books in Medicine
100 e-Proceedings & Tweet Collections
+3.3 Giga Bytes of IP
Translation of 18 books in Medicine: Title page and electronic Table of Contents to SPANISH for 22 Counties speaking Spanish

2.0 LPBI – Technology and Marketing Strategies

2021-2025

Working with BurstIQ leader in Blockchain on architecture of a platform for LPBI’s Content Monetization

A Store on BurstIQ HealthCare Digital Marketplace
Features of the Blockchain Transactions Network: Recommendation Engine, Smart Contracts, Immutable LEDGER, CyberSecurity, Content Promotions
We co-design the architecture to include NLP features to computed on Demand visualization artifacts

Working with Linguamatics/IQVIA on NLP scaling up from a Proof-of-concept to +6,000 articles, all books all e-Proceedings and Tweet collections and Biological images

Will get a quote for Licensing Linguamatics NLP Platform to LPBI
or Licensing Linguamatics NLP Platform to BurstIQ

Working with Montero, Barcelona, Spain on a Marketing Campaign for the SPANISH Edition resulting from Translation of 18 books in Medicine: Title page and electronic Table of Contents to SPANISH for 22 Counties speaking Spanish

Accepted a quote for the Translation job [
Translation of 18 books in Medicine: Title page and electronic Table of Contents to SPANISH for 22 Counties speaking Spanish]
Will review a quote for the joint Marketing Campaign for Latin America with a focus on Mexico, Spain, Argentina

FINANCIALS

LPBI Group is Debt Free

Was financed by myself, while
All the contributions of the Experts, Authors, Writers was performed on an Equity Sharing basis
Sole source of income is represented by Royalties payments every 90 days by Amazon.com for Page downloads and book sales

What are LPBI Group’s offerings?

These six statements, Statement #1, #2, #3, #4, #5, #6 are LPBI Group’s official view on LPBI’s IP Portfolio for venture valuation purposes

Statement #1:

LPBI created an unmatched volume of content created by experts, +3.3 Giga Bytes in TEN Intellectual Property (IP) Asset Classes.

https://pharmaceuticalintelligence.com/2019-vista/

Statement #2:

This volume of content includes four distinct IP asset classes related to curation as a value added secondary research type, out of Ten IP Asset Classes.

Under Licensing agreements of LPBI’s Intellectual Property:
Each of these asset classes can become available to a mutually exclusive potential acquirer in the 12 economic segments listed on LPBI’s Opportunities Map.

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

These are the four Curation-related IP Asset Classes:
IP Asset Class I: Journal articles, +6,000
IP Asset Class II: 18 Books in Medicine
IP Asset Class III: +100 e-Proceedings and Tweet Collections
IP Asset Class V: +5,100 Biological Images in Media Gallery

Statement #3:

For some acquirers these IP Asset Classes are MORE valuable than IP Asset Class I, II, III, V IP Asset Classes that are not related to Curation as a value added secondary research type include the following six:

IP Asset Class IV [composition of methods & platforms]
IP Asset Class VI [Team of Experts – Human Capital]
IP Asset Class VII [Royalties on IP paid by global customers]
IP Asset Class VIII [Website subscribers]
IP Asset Class IX [Intangible Assets: e-Reputation on Social Media by Institutional followings, Testimonials, “Influencer” rankings, 2MM Views of the Website, +500,000 views of LPBI’s Founder, Nominations, Book Page downloads +135,000]
IP Asset Class X [Podcast Library] +250 Podcasts on Interviews with Scientific Leaders exist in Text – been converted into Audio PODCASTS, Work-in-Progress]

Mr. Bahl and Dr. Shertok had ignored Statement #3, above, in their summary on How to position LPBI for a Sale – Conversation with Aditya Bahl https://pharmaceuticalintelligence.com/2021/03/24/how-to-position-lpbi-for-a-sale-joels-conversation-with-aditya-bahl-3-23-2021/ Request access privilege by Contact Us on the website PharmaceuticalIntelligence.com

Statement #4:

Linguamatics/IQVIA brought to the TABLE their NLP platform developed in the last 20 years by co-Founder David Milward, PhD, CS, NLP.

Since 2020, they use BERT technology [originated at Google] for Deep Learning into their established NLP environment for context analysis in text mining
Linguamatics/IQVIA are at the Top of the Top Tier NLP Players
Linguamatics based their Text Analysis of LPBI’s 33 articles and 20 Biological Images on three types of relations:

Genes – Diseases
Diseases – Drugs
Genes – Drugs

They enriched the content context by accessing Ontologies in Public Domain – a routine task in NLP
The Text Analysis with NLP on LPBI’s expert written curations will become a strong offering.
If in 33 [21+12] articles given to them by LPBI, Linguamatics identified 673 relations

Gene – Disease Disease – Drug Gene – Drug

in LPBI’s +6,000 articles Linguamatics NLP system will identify +120,000 relations

ALL Pharma and ALL Healthcare Insurer – ARE NOT AWARE OF +120,000 RELATIONS that machine learning algorithms are yet to unveil by NLP

Statement #5:

NLP for Medical Text Analysis and Blockchain Transactions Network for content monetization are significant technologies for LPBI’s venture valuation purposes

Statement #6:

LPBI’s content on Artificial Intelligence in Medicine was created in earnest for Genomics Volume 2. Respectively,

2.0 LPBI has domain knowledge on Artificial Intelligence in Medicine
2.0 LPBI’s focus is NLP for Medical Text Analysis rather than the BIG field of AI in Medicine

Regarding Artificial Intelligence in Medicine

LPBI has two PORTALS on AI:

AI in Genomics and Cancer

https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/

2021 Medical Text Analysis (NLP)

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/ In 2019, we published Series B, Volume 2:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

Part 3: AI in Medicine this LPBI’s Book

UPDATED on 3/10/2021

Proposed architecture for making a LPBI Business Case “Valuation” is the central problem. It may be worth approaching it in a 3-pronged manner

Framing existing views/downloads into a potential “outreach”
Framing the existing expert network, curation process, NLP pilot and AmazonAdvertising pilot as the execution engine (content creation + commercialization)
Extrapolating the outcomes of AmazonAdvertising vis-a-vis views and purchases to an overall commercial scale

A business valuation would be an outcome of an integrated analysis of the above three.

Framing existing views/downloads into a potential “outreach”

EXISTS

Framing the existing expert network, curation process, NLP pilot and AmazonAdvertising pilot as the execution engine (Visualization/content creation + Content Monetization (commercialization))

Concept born on 3/9/2021

though I started defining already one experiment for Genomics Volume 2 in UK – requested already VAT number to submit the Auction parameters to AmazonAdvertising in UK

Extrapolating the outcomes of AmazonAdvertising vis-a-vis views and purchases to an overall commercial scale

Calls for integration of Point 1 with Point 2. Above

State of Business

Point 2 requires a Design, execution and Analysis of the Analytics provided by AmazonAdvertising

We are in the process of scheduling with Mr. AB, a series of Zoom Meetings to discuss LPBI’s Valuations components. We need the following Zoom Meetings: Zoom Meeting #1 for:

review of our Excel three sheets huge files

Article Views Data, 2012-2020 and Projections to 2025

translation into Projected revenue prospects as presented in our Excel MASTER_FINANCIALS

Sheet #1: 2012-2020, LPBI 1.0 – Ten IP Asset Classes
Sheet #2: 2021-2025, LPBI 2.0 – Six New Strategies: 1. NLP; 2. Blockchain; 3,4,5,6
Combined, 2012-2025

Zoom Meeting #2 for:

review of the Experimental Design for AmazonAdvertising:
the impact of Content Promotion on Content Monetization

Zoom Session #3 for

review the Comparison of RESULTS for
Proof-of-Concept by

LPBI NLP – Wolfram

Linguamatics NLP – Proprietary

Zoom Meeting #4 for: Discussion of the execution of and interim results of AmazonAdvertising in mid way

UPDATED on 3/3/2021

Since 2012, Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, electronic scientific content-creation venture, offering real-time, original scientific content through advanced platform architecture and curation methodologies applied to content in Medicine, Life Sciences, Health Care and Pharmaceutical.

The company’s commitment is to synthesize, analyze and interpret complex, medical and scientific disease information through electronic publishing venues via the cloud to advance the knowledge and research efforts of the scientific and business community. LPBI is recognized as an online leader in scientific curation and dissemination, scientific communication, and medical & pharmaceutical information analysis. Over these years the LPBI Group has generated several large databases of biomedical information, highly curated by teams of scientific and medical experts. These corpuses of knowledge consist of four main sources of biomedical text including:

1) a series of 18 BioMed e-books on cancer, genomics, cardiovascular diseases, metabolomics, immunology, infectious diseases and precision medicine.

2) an Open Access Online Scientific Journal consisting of +6,000 articles in over 730 categories of research, based on an ontology created by the domain knowledge experts of the LPBI Group

3) a corpus of over 70 e-Proceedings of leading Global Scientific/Medical Conferences, reported and curated based on a methodology developed by the LPBI Group producing with one click the digital document, aka e-Proceedings of the conferences and Tweet collections digital documents of all the tweets posted during the last 36 events we covered by LPBI members of the team functioning as Press on behalf of the Conferences organizers.

4) a Gallery of 5,100 Biological Images that populate the +6,000 scientific articles. Each Image has a text legend, and often text is typed on the images to designate details portrayed on the image. Images source is in text format as well.

We are now developing a new platform, based on Blockchain technology, to allow Knowledge Workers to access, use and analyze our extensive structured knowledge databases mentioned in 1,2,3,4, above.

We are seeking Academic partners who can provide natural language processing advice and capabilities for the process of Medical Text Analysis with NLP and Deep Learning. The visualization and other digital products generated by the NLP process for each article and for collections of articles, I.e.,

A. all articles in a Chapter in a Book, and/or

B. all or a selection of Top n articles, rank ordered by # of views from all articles in one or more of the 730 categories of research assigned as main category by the author for the article fetched in the search submitted by a Knowledge Worker accessing LPBI Blockchain interface in the digital store of the premier Health Care Digital Marketplace designed and operated by an IT vendor based in Denver, CO. This vendor is designing LPBI’s Digital Store by our specifications, this design involve embedding of NLP in the blockchain API layer(s).

This new platform under design will allow scalability for the ever-increasing knowledge set we are generating.

The text of an existing article is subjected for test analysis with NLP.
The process generates additional blocks in the article profile:

(1) WordCloud as Abstract (2) Bar diagram of word frequencies (3) hyper-graph(s) and (4) Tree diagram(s) for A and B, above and (5) Domain knowledge expert INTERPRETATION of the visualization. (6) Ability to specify getting this interpretation in English text format and/or getting it in several Foreign languages text.

Content monetization take place by filling up a FORM with all the selections for content download options:

(a) the original article, (b) one or n articles from the article set presented by the Recommendation Engine, (c) original images and NLP generated visuals (d) NLP results interpretation by domain knowledge experts (e) choice of English or several Foreign languages for the text of these interpretations

Features of the Blockchain Transactions Network will include: Permissions, Immutable LEDGER for the payments taking place prior to Permission grants to download contents, Smart contracts, Cybersecurity of the IP

We have successfully beta tested NLP algorithms on small-representative, structured datasets of articles, Text files and Biological images files.

This proof-of-concept is now expected to compare the results LPBI generated by using Wolfram NLP Language for Biological Sciences vs the results now being produced by LINGUAMATICS, a lead NLP vendor for the Pharma industry.
Our team and that vendor are using the same data files we produced for Phase 2 of the Proof-of-Concept project.

Our goal is to provide Knowledge Workers with a one-stop shop for Biomedical information and the means to analyze this information on an as-needed basis, i.e., the Knowledge Worker will be able to specify the sub universe of articles on which NLP algorithms are applied. The Blockchain platform with the embedded NLP will retrieve any configuration of articles and will generate the visualizations for the Text analysis with NLP.

Additional details are included in the following article:

2.0 LPBI is a Very Unique Organization

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

UPDATED on 2/25/2021

2.0 LPBI Team members are executing the following

Strategic Plan for 2021 – 2025

Initiative #1:

One entry for WIKIPEDIA to be recreated in 1Q 2021

Work-in-Progress

1.0 LPBI entry

2.0 LPBI entry

Founder of 1.0 LPBI and 2.0 LPBI – Aviva Lev-Ari, PhD, RN

Initiative #2:

New WebSite Design

Two Site Map Proposals for LPBI’s New Web Site
Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/

Initiative #3:

Six New Strategies for 1.0 LPBI Group’s Four of the Ten Intellectual Property Asset Classes:

Journal articles – N= +6,000 [IP Asset Class I] Books – N=18 [IP Asset Class II] e-Proceedings & Tweet Collections – N=100 [IP Asset Class III] Biological Images – N=5,100 [IP Asset Class V]

To complete the Proof of Concept in Medical Text Analysis with NLP, ML-AI

• LINGUAMATICS got our Phase 2 Proof-of-Concept data files on 2/24/2021

LPBI Team uses same data files using Wolfram’s NLP

we need a dashboard infrastructure Off-the-Shelf i.e., Linguamatics product: Insights Hub using NLP

Content monetization: to sell Articles, Insights, Visualization and Bundled Services/Products

• Blockchain Vendor in CO will revise quote for design of a Digital Store for LPBI in theirs HEALTHCARE Digital marketplace

we need a Blockchain Transactions System with features of: Recommendation Engine, Immutable LEDGER, Smart contracts, Permissions and cyber security for LPBI IP

The six 2.0 LPBI new strategies that represent the Pipelines for 2021 – 2025 include the following:

Strategy #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Strategy #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: a Partner has lined them up and are willing to build the Front End

To accomplish Strategy #1 and Strategy #2 – a bridge investment is needed for:

SCALING up NLP on four IP Asset Classes [Journal, Books, e-Proceeding, Biological Images], and
Finance the BLOCKCHAIN IT infrastructure development and DATA indexing and Migration for Content Monetization: Vendor’s Quote and monthly fees till the Exit
Finance the Content Promotion REQUIRED to generate transactions and the development of B2C opportunities
Finance marketing effort needed for the development of B2B opportunities in Pharma & Healthcare Insurance

Strategy #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

Strategy #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL

Strategy #5: Joint venture with Biotech Accelerator for Drug Discovery:

We worked together in 2015-2016 for 2 years – Plan for 2020-2021: Galectins explored as drug-able by Scientists using Synthetic Biology to design new drug molecules

INTERNS are joining after Labor Day – they need to gain some LAB Flavor in return for working as Volunteers @LPBI projects: SEE

2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates

2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP) 9/2020 – 9/2021

Strategy #6: e-Books Translations into Japanese, Spanish, Russian

Decision taken to Translate to Foreign languages only two artifacts:

A. BioMed e-Series: 18 Volumes – electronic Table of Contents of each Volume https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/

Contains for each Book three LINKS:

BLUE – is the link to the Book on Amazon to see number of Pages & Price, Cover Page, Book Summary and Look Inside

RED – is The electronic Table of Contents (eTOCs) – Published as an article for each book on Linkedin

GREEN – is the ENTIRE book in our Cloud – In case you decide that one or all of below listed sections are needed as well for the Spanish e-Readers

B. Domain knowledge Expert’s INTERPRETATION of the NLP visualization results

For TRANSLATION from English to Spanish, we were recommended the following two AGENCIES:

UBIQUS https://www.ubiqus.com/es/ +34 915 400 540 gestionspain@ubiqus.com Caleidos http://www.caleidos.es/ +34 916 252 180 maria.munoz@caleidos.es

Initiative #4:

New Industry Partnerships for 2.0 LPBI: 2021 and Beyond

The partnerships are selected to support the development of the six New Strategies: NS #1, #2, #3, #4, #5, #6 listed in Initiative #2, above and described in great details, below

Explorations with a Leader NLP Vendor in Healthcare
Explorations with Blockchain Vendors in the Healthcare Sector
Explorations with New Audio & Video Technologies for Podcasting
Explorations with Text to Audio Vendors
Explorations with Synthetic Biology for Drug Discovery
Explorations with Translation Agencies in Foreign Languages

UPDATED on 2/1/2021

Milestone achieved today

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

Thought on the transition

One Possible Strategy for an Acquisition is via a SPAC https://pharmaceuticalintelligence.com/2021/01/30/one-possible-strategy-for-an-acquisition-is-via-a-spac/ UPDATED on 1/26/2021 – This Update is on Medical Text Analysis – Proof-of-Concept Project

I was very happy to write for you the RSI Recommendation Letter.
Congratulations for the TOP THREE placement on Model United Nations international conference
I have infront of me C;ark Scholar – will work on it hopefully tonight. WITHOUT your e-mail about it – IT WAS BURIED in the Inbox of 1/8/2021
NO Texas Tech e-mail in my Inbox. I searched for From: Texas Tech – No results
Yes, Genomics Volume 2 will be yours for scaling from Proof-of-Concept to ONE Volume in Genomics – TILL Dr. Williams send us the following:
Expansion A to Proof-of-Concept
ONE article in Cancer he selected from the 16 AND
For that Chosen Article – what ITS is Main Category of research AND
In which Chapter in Cancer Volume 1 it is AND
How many OTHER articles are in this Chapter N=X
He will make list of Articles Names and URL
Expansion B to Proof-of-Concept
HE will go to THIS Main Category of research
He will select N=X numbers of articles from THIS Main Category of research
He will make list of Articles Names and URL
Dr. Williams will send that information 6 to 15, above to Madison, Danielle and Aviva
INSTRUCTIONS for 11 and for 15, above:
Madison will handle ALL development and #11, above
Danielle will get instructions from Madison and handle #15, above
FOR 11 and for 15, above – we need the following at PRIORITY #1 [expected by LINGUAMATICS – ASAP] – After Priority 1 is accomplished we MOVE to Priority 2
PRIORITY #1 Madison : For 11 – create ONE MS Word File for each article on Article Name AND create ONE Big file for all the articles in a sequence
PRIORITY #1 Danielle : For 15 – create ONE MS Word File for each article on Article Name AND create ONE Big file for all the articles in a sequence
OUTPUT of 21 and of 22, above – AVIVA WILL e-mail to Jane Reed, VP Life Sciences, LINGUAMATICS – her team will perform NLP on the two TEXT files
Expansion C to Proof-of-Concept
Madison uses 21, above to produce: WordClouds [WordItOut + Wolfram], BAR diagrams one per article, Hyper-graph for each article and ONE Tree Diagram for the collection of articles
Danielle uses 22, above to produce: WordClouds [WordItOut + Wolfram], BAR diagrams one per article, Hyper-graph for each article and ONE Tree Diagram for the collection of articles
WE WILL COMPARE 25 AND 26 WITH THE OUTPUT FROM LINGUAMATICS
We will need to discuss with LINGUAMATICS the joint Presentation at the Healthcare Insurer.
SCALLING UP FROM PROOF-of-CONCEPT to Cancer Volume 1 and Genomics Volume 2 – BEGINS
Madison, goes back to 5, above, works of Chapter 1 as an Article Collection for in Genomics Volume 2
Danielle – Starts on Cancer Volume 1, Chapter 1 as an Article Collection
Amanda Kaur – will perform HER Proof-of-Concept on Genomics, Volume 1, Chapter 21: CRISPR THEN start Genomics Volume 1, Chapter 1 to 20.
Adina will start her Proof-of-Concept on 13 Articles in CVD using the Templates created by Madison
The Medical Text Analysis Team will decide if the STORAGE of the GRAPHICS post NLP Processing will be stored in DropBox or in GoogleDocs

UPDATED on 1/25/2020 – This Update is on B2C been served by blockchain transaction network and and B2B been served by Special installations

Our Opportunities Map in this link describes the Value Drives and the Business Functions for using our products. It includes names of targeted companies.

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Twelve Economic Segments for LPBI Group’s IP – Prospects for Transfer of Ownership

Holding Companies, Investment Bankers and Private Equity
Information Technology Companies – Health Care
Scientific Publishers
Big Pharma
Internet Health Care Media & Digital Health
Online Education
Health Insurance Companies & HMOs
Medical and Pharma Associations
Medical Education
Information Syndicators
Global Biotech & Pharmaceutical Conference Organizer
CRO & CRA

From the List of 12 Economics Segments, above, one realizes that the market is very big for the

Existing products and for the
Products generated by the process of Text Analysis using Machine Learning algorithms. In addition,
Coupling of Existing products with new graphical products generated by ML with
an IT infrastructure with all the features of a Blockchain Transaction Processing Network represents the necessary and sufficient conditions for storage, data management and data exchange needed for enabling the following of 2.0 LPBI, 2021-2025 three missions:

Insights from the Graphics produced by ML get the Interpretation of experts for the Medical Text semantically analyzed with Natural Language Processing, Machine Learning, Artificial Intelligence algorithms
Content Monetization on a Blockchain Transaction Network in a Digital Store of a Healthcare Digital Marketplace allowing for B2C
Content Monetization on a Blockchain Transaction Network serving special installations for B2B

Namely,

Special Installations for B2B for Segment 2 and Segment 4, above – will run in parallel to a Digital Store of a Healthcare Digital Marketplace allowing for B2C

Examples for Special Installations for B2B are presented, below for Segmenr 2 and Segment 4:

Economic Segment 2: Information Technology Companies – Health Care

Amazon Web Services (AWS),
Apple-Health,
IBM Watson,
Microsoft-Health,
Oracle-Health,
SAP Intel-Health,

Economic Segment 4: Big Pharma

J&J,
Pfizer,
TEVA

UPDATED on 1/13/2021 – This Update defines the Outputs of NLP on LPBI content in Text and Image format

We will have from our IT Vendor a BLUEPRINTS for the content monetization system design with all the components laid out in a workflow for a production process to incorporate two sources of data:

1.0 LPBI four IP Asset Classes: I, II, III, V will be available for monetization

The Design include all monetization Features to incorporate the 2.0 LPBI NEWLY TO BE CREATED PRODUCTS by NLP integrated at the article level with the 1.0 LPBI IP.

We will generate four Text Analysis products, like the FOUR outcomes of NLP included in the Proof-of-Concept:

NLP Products: Will be available for monetization as 2.0 LPBI IP:

WordClouds,
Bar charts,
Hyper-graphs and
Expert Interpretation in English and Foreign Languages

PHASE I: All Articles in ALL Books at the Chapter Level – THEY WILL HAVE:

WordClouds,
Bar charts,
Hyper-graphs and
Expert Interpretation in English and Foreign Languages

For:

Series A: 6 volumes,

Series B: 2 volumes

Series C: 2 volumes

Series D: 4 volumes – 1, 2&3 in one Book, 4

Series E: 4 volumes

Total 17 Books for 18 Volumes

PHASE II: All Articles Not in Books and Not as e-Proceedings – THEY WILL HAVE:

WordClouds,
Bar charts,
Hyper-graphs and
Expert Interpretation in English and Foreign Languages

PHASE III: 60 e-Proceedings + 36 Tweet Collections – THEY WILL HAVE:

WordClouds,
Bar charts,
Hyper-graphs and
Expert Interpretation in English and Foreign Languages

PHASE IV: 5,100 Biological Images – THEY WILL HAVE:

WordClouds,
Bar charts,
Hyper-graphs and
Expert Interpretation in English and Foreign Languages

UPDATES on 1/8/2021 – This Update is on Strategy #1 and Strategy #2

Description of 2.0 LPBI

Medical Text Analysis using NLP, ML-AI on our own content generated, 2012-2020: 6000 Journal articles, 17 e-Books in Medicine, 100 e-Proceedings & Tweet Collections and +5000 Biological images Content Monetization system development for (a) EXISTING digital products and (b) the results of Medical Text Analysis using NLP, ML-AI: WordClouds & Hyper-graphs

LPBI created a e-Scientific Publishing venture second to none – based on ~2MM Views has projected revenues to $ZZZ MM
The Content Monetization Cloud-based IT System DESIGN will have features of Blockchain transaction network: PERMISSIONS, LEDGER, RECOMMENDATION ENGINE
System integration for 1 and 2

In addition, DESIGN of CONTENT PROMOTION campaigns

We need to be teamed up with a Partner or an inside Group to XXX for the DESIGN of CONTENT PROMOTION campaigns for (1.0 LPBI IP[digital products: journal articles, e-Proceedings, Tweet Collections, Biological images]
Upon progress with content promotion for existing digital products, same effort needs to be developed for 2.0 LPBI IP, named, the results of Text Analysis with NLP, ML-AI. This newly created IP, as well needs DESIGN of CONTENT PROMOTION campaign for WordClouds, Hyper-graphs and Domain Expert Interpretation of the Hyper-graphs in foreign languages

All developments realted to Technologies applied by 2.0 LPBI are to be found in the following article. Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V Author: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/

UPDATED on 12/22/2020 – This Update described four initiatives for 2.0 LPBI

Development and Execution of 2020-2021 Vision for 2.0 LPBI

https://pharmaceuticalintelligence.com/vision/

2.0 LPBI, 2021 – 2025, will pursue four initiatives:

Initiative #1. Wikipedia presence

Initiative #2. New Web Site Design

Two Site Map Proposals for LPBI’s New Web Site

Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/

Initiative #3. Six New Strategies

Initiative #4. New Technology Partnerships for 3.1 to 3.6, below

Initiative #3 – Six New Strategies: Overview description

UPDATED on 12/30/2020 – This Update defines a Longitudinal Profile for the Unit Case: “Article”

For the DESIGN of IT Infrastructure for Monetization, the following is an essential

DEFINITION for “PROFILE of an Article”:

1.0 LPBI BEGINS

Monetization of 6,000 Digital Products – A Unit Case: A Journal Article

5.0 Article Title

5.0.1 Article URL

5.0.2 Author 1: Name

5.0.2.1 Author 2: Name

5.0.2.2 Author 3: Name

5.0.2.3 Author 4: Name

5.0.3 Date of Publication

5.0.4 # Words

5.0.5 # Views since Published to DATE

5.1 Is the article in a Book?

5.1.1 Article is not in a Book only in the Journal

5.2 Article is in a Book – In which one(s)?

5.2.1 LPBI Series A

5.2.1.1 Volume 1

5.2.1.2 Volume 2

5.2.1.3 Volume 3

5.2.1.4 Volume 4

5.2.1.5 Volume 5

5.2.1.6 Volume 6

5.2.2 LPBI Series B

5.2.2.1 Volume 1

5.2.2.2 Volume 2

5.2.3 LPBI Series C

5.2.3.1 Volume 1

5.2.3.2 Volume 2

5.2.4 LPBI Series D

5.2.4.1 Volume 1

5.2.4.2 Volume 2

5.2.4.3 Volume 3

5.2.4.4 Volume 4 [Dr. Williams and Dr. Irina are adding editorials, NOW]

5.2.5 LPBI Series E

5.2.5.1 Volume 1

5.2.5.2 Volume 2

5.2.5.3 Volume 3

5.2.5.4 Volume 4

1.0 LPBI ENDS

2.0 LPBI BEGINS: Medical Text Analysis (NLP, ML, AI) (SaaS) and

Monetization of Text Analysis Results as Products (Blockchain as a Service (BaaS)

5.3 Does article have the Text Analysis features:

5.3.1. a WordCloud – needs to be stored in graph file of WordClouds

5.3.2. # words used

5.3.3. Hyper-graphs – need to be stored in graph file of Hyper-graphs

5.3.3.1 One Hyper-graph for All articles in a Book Chapter

5.3.3.2 One Super-graph for All articles in one or more Categories of Research – need to be stored in graph file of Super-graphs

5.3.4. Domain Expert interpretation for 5.3.3.

5.3.4.1 Domain Expert interpretation for 5.3.3.1

5.3.4.2 Domain Expert interpretation for 5.3.3.2

5.4 Audio File added to Article

5.4.1 In place – Audio file type [Text to Audio]

5.4.1 SoundCloud file

5.5 Article Titles was translated to

5.5.1 Spanish

5.5.2 Japanese

5.5.3 Russian

12/30/2020 – This Update is on Medical Text Analysis with NLP

We are facing FIRST the following challenges:

1. When we apply NLP on ONE article NLP yields a WordCloud

2. When we apply NLP on all the articles in ONE book’s electronic Table of Contents (eTOCs)

NLP yields a Hyper-graph

3. When we apply NLP on all the Hyper-graphs of one Books (all chapters)

NLP yields a Super-graph

Linguamatics has capabilities for using as input

1,2,3, above and can be combined INSIGHTS from LPBI CONTENT with Disparate Data sources for a newly defined purpose

It is that stage WHEN 1.0 LPBI IP will yield a Software as a Service (SaaS):

If we RUN NLP on 1.2,3 and Disparate Data Source:

Like EMR as a data source

Like Drug Formulary or Clinical Trials as a data source

The output creates a different set of Recommendations:

• If EMR then Insights will serve a Healthcare Insurer

• If Drug Formulary and Clinical Trials then Insights will serve a Big Pharma

UPDATED on 12/28/2020 – This Update is on Translation from English to Spanish the eTOCs of 18 books in Medicine

New:

I had Zoom with C. Cxxxx in Barcelona. She works for a Pharmaceutical Publisher in Spain

• She will present at 12:45PM EST on 1/12/2021 – Our 2.0 LPBI first Global Zoom Updates to agenda on Calendar. She is sending us contacts and may

• Translate all 16 electronic Table of Contents of the e-Books to Spanish and

• Connect us with Marketing Departments in all big Pharma and market entry into Latin America Pharmaceutic Publishing sectors

New:

Progress was achieved by our Medical Text Analysis Team using NLP, per Madison Davis e-mail of Yesterday.

WHEN that is completed and AWS-IT Cloud Vendor will have an architecture to scale

• We will Zoom with Dr. R G of XXX the Healthcare Insurer awaiting for the Proof of Concept

New:

I requested JP, AWS and another AWS person to help me be introduced to two different departments at AWS:

1. Decision makers of who to talk to about having 2.0 LPBI become a participant at AWS Marketplace offering Services accessible to all other AWS Marketplace members

2. Decision makers of who to talk to in the AWS Venture Acquisition Department.

• They will get back to me.

New:

We need an IT Cloud Vendor for

1. Scaling from Proof of Concept to Production NLP, ML, AI using AWS infrastructure

2. Architecture to monetize IP Assets – AWS HyperLedger with some functionality of Blockchain vs Blockchain forthcoming revised Quote from YYYY

3. IT Cloud Vendor to present with us 1, above to Dr. R G on xxx Healthcare Insurer – as our Business Partner

4. For our Exit: the output of IT Cloud Vendor and YYY (blockchain leader) and zzzz (NLP in Life Sciences Leader) on 1 & 2 above – served as pipeline business development PLAN AND INVESTMENT COSTS to be Addendum to Master_Financials Excel File

3.1 NLP, ML, AI on our four Corpuses of Intellectual Property (IP) assets:

12/22/2020 – This Update describes LPBI’s IP Asset Classes appropriate for Text Analysis with NLP

3.1.1 1.0 LPBI IP Asset Classes relevant for AI-ML

3.1.1.1 6,000 journal articles

3.1.1.2 16 eBooks in Medicine

3.1.1.3 100 eProceedings and Tweet Collections of top Biotech and Medical Global Conference we covered in Real Time – See Press Coverage

3.1.1.4 Gallery of 5,100 Biological Images

3.1.1.5 Content aggregation via Categories of Research combinations – 720 Categories of Research make the Journal Ontology

3.1.2 NLP Artifact Files & Database

3.1.2.1 WordClouds for 3.1.1.1 – 3.1.1.3

3.1.2.2 Number of Words in use for WordCloud generation

3.1.2.3 Hyper-graphs: Graph Files & Databases for 3.1.1.1 – 3.1.1.3

3.1.2.4 Experts Interpretation of Hyper-graphs: Text files & Graph Files Databases

3.2 Monetization of 3.1 [3.1.1 & 3.1.2] using Blockchain Transaction Network, digital store in Healthcare Digital Marketplace

3.3 Podcast Library Development

3.4 Conversion of 3.1.1.1– 3.1.1.3 from English Text to English Audio

3.5 Joint venture on Synthetic Biology in Drug Development of Galectins with SBH Sciences, Inc at ABI-LAB

3.6 Conversion of 3.1.1.2 [electronic Table of Contents] to Foreign Languages: Japanese, Spanish, Russian

UPDATED on 11/27/2020 – This Update describes 2021-2025 Vision for LPBI

2.0 LPBI Executive Summary

2.0 LPBI Brochure

Password protected document – request access by Contact us

Knowledge PORTALS System (KPS) @LPBI

Knowledge PORTALS System (KPS) @LPBI is an initiative launched in September 2020 to manage the content creation @LPBI by our Final Improvement Team (FIT) members during the Transition Period that started on March 14, 2020 with the Launch of the Coronavirus Portal to cover eight aspects of the SARS-CoV-2 Pandemic @LPBI and which will end when CDC will announce that this Pandemic is over.

2020 VISTA 1.0 LPBI

https://pharmaceuticalintelligence.com/2019-vista/

1.0 LPBI Executive Summary

1.0 LPBI Brochure

Password protected document – request access by Contact us

Elevator Pitch

2.0 LPBI Group’s Team Members

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

2.0 LPBI Executive Summary

A New Team was put in place for the development of the pipelines defining the future prospect of 1.0 LPBI Group’s portfolio of IP and the opportunities for 2.0 LPBI Group’s Team.

2.0 LPBI Group’s Team

2020-21 Visions include the new Pipelines and the Strategic Plans for 2.0 LPBI: 2021 – 2025

https://pharmaceuticalintelligence.com/vision/

LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible. The challenge for the future is the development of several, i.e., the following six new strategies for creation of Value added Services and Products.

2.0 LPBI Team members are executing the following

Strategic Plan for 2021 – 2025

Initiative #1:

One entry for WIKIPEDIA to be recreated in 1Q 2021

Work-in-Progress

1.0 LPBI entry

2.0 LPBI entry

Founder of 1.0 LPBI and 2.0 LPBI – Aviva Lev-Ari, PhD, RN

Initiative #2:

New WebSite Design

Two Site Map Proposals for LPBI’s New Web Site
Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/

Initiative #3:

Six New Strategies for 1.0 LPBI Group’s Ten Intellectual Property Asset Classes

To complete the Proof of Concept

• we need a dashboard infrastructure Off-the-Shelf i.e., Linguamatics product: Insights Hub using NLP

To sell Articles, Insights, Visualization and Bundled Services/Products

• we need a Transaction System, I.e., a Healthcare Blockchain vendor

The six 2.0 LPBI new strategies that represent the Pipelines for 2021 – 2025 include the following:

Strategy #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Strategy #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: a Partner has lined them up and are willing to build the Front End

Strategy #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

Strategy #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL

Strategy #5: Joint venture with Biotech Accelerator for Drug Discovery:

We worked together in 2015-2016 for 2 years – Plan for 2020-2021: Galectins explored as drug-able by Scientists using Synthetic Biology to design new drug molecules

INTERNS are joining after Labor Day – they need to gain some LAB Flavor in return for working as Volunteers @LPBI projects: SEE

2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates

2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP) 9/2020 – 9/2021

Strategy #6: e-Books Translations into Japanese, Spanish, Russian

For TRANSLATION from English to Spanish, we were recommended the following two AGENCIES:

UBIQUS https://www.ubiqus.com/es/ +34 915 400 540 gestionspain@ubiqus.com Caleidos http://www.caleidos.es/ +34 916 252 180 maria.munoz@caleidos.es

Initiative #4:

New Industry Partnerships for 2.0 LPBI: 2021 and Beyond

The partnerships are selected to support the development of the six New Strategies: NS #1, #2, #3, #4, #5, #6 listed in Initiative #2, above and described in great details, below

Explorations with a Leader NLP Vendor in Healthcare
Explorations with Blockchain Vendors in the Healthcare Sector
Explorations with New Audio & Video Technologies for Podcasting
Explorations with Text to Audio Vendors
Explorations with Synthetic Biology for Drug Discovery
Explorations with Translation Agencies in Foreign Languages

2.0 LPBI – 2021 and Beyond

The New Strategies: NS #1, #2, #3, #4, #5, #6

Updated on 12/28/2020

WHAT IS IN THE INVENTORY?

In 2021 we have for Monetization:

1. Four IP Asset Classes:

(a) 6,000 articles

(b) 16 Books & each article in every Book

(d) 5,100 Biological Images inside curated content

2022-2025 – A Strategy of New Product Development (based on existing Four IP Asset Classes) by Type:

2. 6,000 Articles as Audio Files – embedded SoundCloud file inside the articles, one per article

3. 6,000 WordClouds

4. 6,000 NLP HyperGraphs – Graph files or Images

5. Each article has on average ~6 Categories of Research –

5a. When a Topic is selected the computer needs to present 10-12 alternative related articles from several categories assigned by the Author by his/her selection of cardinal Research Categories – A Smart guided Recommendation Engine

5b. One hyper-graph for all the articles in One category of Research the article belongs to,

5c. One hyper-graph for each of the “on average ~6 Categories of Research for each article”

5d. New Corpus of hyper-graph Expert Interpretation: searchable, sorted and reusable

• How could we present a universe of up to 12 articles to choose from BUT allow to download one or more from the alternative of 12 ONLY after a payment for each had credited 2.0 LPBI account. That activity requires Blockchain not only a PayPal

• Who will perform FULFILLMENT – approval of the download only of the article ID matched to the one paid for by the e-Reader.

You pay for one download once.

You pay for one download of all the choices you browse to select only one

• that is a feature that Blockchain offer

• prevention of downloading items Not paid for

• storage of 1 to 5, above including 6,000 X new types of the original article: Audio or Translation

Blockchain will allows selling 1 to 5, above – that is Blookchain as a Service (BaaS)

2021 we have for Monetization – Continued:

6. 16 Books in English

2022-25

7. 16 Audio Books in English (or other foreign languages)

8. XYZ articles for sell as “Articles published in Books” vs “Journal Articles”

9. 16 Books in Spanish – May be also 16 Audio books in Spanish

10. 16 Books in Japanese – May be Audio books in Japanese

11. 16 Books in Russian – May be Audio books in Russian

If we sell e-Books on Amazon.com we get 35% of book price

• Page downloads equivalent to 52 books 📚 not sold – 125,000 Page downloads as of 8/31/2020

• If Books are ready for FULFILLMENT on Digital Store in Blockchain Marketplace THEN 7 to 11 above is at Full book price not at 35% we will charge for Page download $2.25 vs 0.005 cents paid to us as Royalties

12. 2021 we have for sell 60 eProceedings and 36 Tweet Collections – Profile Meta Data is different than a Journal Article or an e-Book

We have no platform to sell them

• Blockchain will do the job

AWS is what we wish to consider

Amazon Advertising – we will need to use. I set up an experiment for Genomics Volume 2 in UK, my budget is $200

90 days of advertisement AUCTION 0.45 GBP per ad.

I need to get VAT from Amazon UK to place the Advertisement

Requires Experimental Design: Which book in which Country, duration of Experiment by advertisement using AUCTION
Compare analytics – the e-Book Sales vs cost of Advertisement across several Books in different times of the Year

We have a quote of $$$ to handle (Data engineering included) – Only of the following LPBI IP Asset Classes:

• 6000 article

• 16 Books

• 100 e-Proceedings/Tweet Collection

@@@@@@@@@@@ THAT does not include the other numbers of 1 to 12 above

Who will update the Digital Store with new items to be indexed as they become available

Running NLP on LPBI Content Types will yield a New Corpus of Knowledge: a DB of Hyper-graphs

• all articles in Research category “cell biology” will yield a

Hypergraph, hg1

• all articles on Cancer cell biology will yield a

Hypergraph, hg2

• all e-Proceeding of Cancer Conferences will yield a

Hypergraph, hg3

• Genomics volume 1 will yield a Hypergraph, hg4

• Cancer Volume 2 will yield a Hypergraph, hg5

We need a DB for Hyper-graphs: hg(1) to hg(n)

• Hyper-graphs need to be stored in a DB of graph files or of Images – annotated and searchable

AVAILABLE for download and one needs to pay for the download

each Hyper-graph will be CREATED FROM PROPRIETARY Content, aka, the LPBI IP subjected to Text Analysis DONE BY ML-NLP-based algorithms
NOT ALIKE to running NLP on PubMed, Content is in the public domain in a searchable DB by KEYS: keyword/author name/date of publication

we execute on 2.0 LPBI Medical Text Analysis Strategy

THEN

monetization is

NOT only of the

• IP Asset Class I (Journal Articles), II (e-Books), III (e-Proceedings+Tweet Collections), and V (Image Gallery)

BUT

• all the RESULTING Products from 1 to 12, above

We will be developing TWO new Services using our content:

Strategic Concepts Defined

1. Insights as a Service [IaaS] – Consultancy with Big Pharma on our Insights from the Curations

Medical Text Analysis – Features of Linguamatics Infrastructure SW:

infrastructure for text analysis with NLP, AI/ML for lIfe sciences – We need the dashboard for the interpretation after the hyper graphs are created by the NLP algorithm – They have it.
We will get a quote from Linguamatics for a new Off-the-Shelf Suite – We will use it for LPBI’s cost of performing medical text analysis for the Health-Care Insurer at UT. That suite is part of materials + labor used in billing.
We need to find an Off-the-Shelf Suite that has

Data ingress –
Text processing with NLP, AI/ML
Output with visualization

Analytics of patterns known in the Life Sciences – comparison of what is found in our Text vs Patterns representing known relations in the biological sciences. Linguamatics has developed the infrastructure to host (a) Dictionaries for Pharmaceutics Formulary (b) Biological Pathways (c) Medical Terminology (d) PubMed LPBI will be more valuable, credible and authentic if we can demonstrate:

Understanding of the infrastructure required to enable medical text analysis of LPBI’s IP
Understanding the ecosystem of vendors for such an undertaking: medical text analysis with NLP, AI/ML
If we claim that our curations are unique, then we should be able to perform the text analysis and show visually the insights uncovered using the hypergraphs known in the Life Sciences – they have the suite we need to use to do the job of medical text analysis.
We will get a quote and compare it with Wolfram Environment for NLP
We do our homework, get prices and relationships with vendors lined up
We are ready to ROLL if the Acquirer supports the directions

We are lining up all the players that will enable us to develop the CONCEPT of a full flag Service Description for:

A. Insights as a Service (IaaS):

What 2.0 LPBI is including in a consulting program for Big Pharma for $X00,000 an engagement with a Demo

a.1 Medical Therapy selected – Expert input

a.2 Categories of Research in the Journal that contain the articles of relevance – Expert input

a.3 TEXT ANALYSIS process using platform I.e., Linguamatics or other vendor

a.4 Visualization of Solutions

a.5 Recommendations to Big Pharma

We need several a.1, each one for another medical indication per our Cardiovascular, Genomics, Cancer, Immunology, Precision Medicine – content universes

2. Blockchain as a Service [BaaS] for transactions for content information syndicator

We are not making any expense; we need few bids to understand the cost involved in getting the infrastructure to sell one article for $30

Without such an infrastructure we will not be able to monetize our content. ALL WE HAVE is CONTENT and PEOPLE.
If we have our own a Business Account for LPBI on PayPal.com that will record the AR and AP, then
Who will do fulfillment? namely, displaying the articles to choose from, allowing download of the content and monitoring access only to the articles downloaded – PAY per CLICK model –
PayPal does not do that. Indexing the N=6,000 is step one. Search and display several related articles to select only the one needed.
Upon selection, access permit needs to be granted online and the Transaction need to be recorded.

LPBI is more valuable, credible and authentic if we are able to demonstrate:

Understanding of the infrastructure required to enable monetization of the IP
Understanding of the ecosystem of Healthcare Blockchain vendors for such an infrastructure
If we claim that one article would sell for $30, then we have to figure out what it takes to enable a customer to pay per click and download the content he/she chooses from a selection of related articles presented to him/her by the system

B. Blockchain as a Service (BaaS)

What 2.0 LPBI will be narrow casting as an offering?

a.1, a.2, a.4, a.5, above – bundled for Customers of a HealthCare Blockchain Marketplace Exchange – we need relations with all aggregators of Healthcare Customers to promote our Insights as a Service (IaaS)

Healthcare Blockchain Market place is where we plan to sell IaaS

Our Digital Store on the Exchange which stores all our products: I.e., journal articles:

Article #1

Article #2

.

Article #6,000

Blockchain products indexed will enable to do a.2: search by category, it will as well enable to store a.4 and a.5, above

It is only a.3, above – the actual NLP, ML Text Processing and Analysis will be done outside the blockchain on a platform like Linguamatics’ Insight Hub

We plan to sell Insights as a consultancy that requires Indexing and storage of Insights per Medical Indication – that is similar to the article inventory “bar coded” by an n-dimensional indexing data scheme

Following the Text Analysis phase – the Text Analysis Outcomes will be stored for reuse and recombination ready for Trade.

The Blockchain Transaction System will provide these features of the infrastructure as well as will record the trade and grant access to

• select

• pay

• download selected content

2.0 LPBI would use Blockchain creatively NOT for only what it was originally designed for, but also for UP-SELLING 1.0 LPBI content:

SELLING 1.0 LPBI content is

• downloading one article for $30

n=6,000

UP-SELLING 1.0 LPBI content is

• downloading Insights generated by Text Analysis using NLP, AI/ML.

SELLING 1.0 LPBI Graphic Images $100

n=5,100

UP-SELLING 1.0 LPBI Graphical visualization of semantic relations in Image format is

• downloading Visualizations of hypergraphs generated by Text Analysis using NLP, AI/ML

When 2.0 LPBI Sell an item and a Customer pay 💰 a Transaction Network infrastructure, I.e., Blockchain, needs to be custodian of the trade

We will need to Price Insights and Visualization PRODUCED in the Text Analysis phase.

IaaS and BaaS are designed ON TOP OF 1.0 LPBI Products, IaaS and BaaS need to be explained as 2.0 LPBI strategy:

We need to complete the Proof of Concept to get SAMPLES of

• Insights

• Visualization of Semantic Hypergraphs

• Bundle for IaaS consulting the following components:

(a) Articles

(b) graphics

(d) visualization of hyper-graphs generated as an outcome from the Text Analysis with NLP phase

To complete the Proof of Concept

• we need a dashboard infrastructure Off-the-Shelf i.e., Linguamatics product: Insights Hub

To sell Articles, Insights, Visualization and Bundled Services/Products

• we need a Transaction System, I.e., a Healthcare Blockchain vendor

Perspectives on the INTEGRATION of NLP and Blockchain

2021 we have for Monetization:

1. 6,000 articles

2022-25 we will have for Monetization:

2. 6,000 Audio Files

3. 6,000 WordClouds

4. 6,000 NLP HyperGraphs

5. 5,100 Biological Graphs

6. Each article has ~6 Categories of Research – When a Topic is selected the computer needs to present 10 alternative related articles from several categories assigned by the Author

Implementation issues addressed:

#1: Infrastructure design issues

How you present a universe of up to ten articles to choose from BUT allow to download one or more from the alternative of 10 ONLY after a payment for each had credited 2.0 LPBI account.

That activity requires Blockchain not only a PayPal

Who will perform FULFILLMENT – approval of the download only of the article ID matched to the one paid for by the e-Reader.

You pay for one download one.

You pay for one download all the choices you browse to select only one

• that is a feature that Blockchain offer

• prevention of downloading items Noy paid for

• storage of 1 to 6, above including 6,000 X new types of the original article

Blockchain will allows selling 1 to 6, above – that is Blockchain as a Service (BaaS)

In 2021 we have for Monetization:

7. 16 Books in English

In 2022-25 we will have for Monetization:

8. 16 Audio Books in English (or other foreign languages)

9. XYZ articles for sell as “Articles published in Books” vs “Journal Articles”

10. 16 Books in Spanish

11. 16 Books in Japanese

12. 16 Books in Russian

BioMed e-Series: If we sell on Amazon.com

we get 35% of book price
Page downloads of 125,000 equivalent to 52 book 📚 not sold

If Books are ready for FULFILLMENT on Digital Store in Blockchain Marketplace THEN

7 to 12 above is at Full book price not at 35%
we charge for Page down load $2.25 vs 0.005 cents

13. 2021 we have for sell 60 eProceedings and 36 Tweet Collections

We have no platform to sell them
Blockchain will do the job

AWS has a platform allowing to Integrate NLP with Blockchain

Amazon Advertising – we will need to use without Narrow casting and Promotion – no sales will occur

I set up an experiment for Genomics Volume 2 in UK, my budget is $200

90 days of advertisement AUCTION 0.45 GBP per ad.

I need to get VAT from Amazon UK to place the Advertisement

We have a quote of $XXX,XXX from a blockchain vendor in CO to handle: IP Assets I,II,III

• 6000 article

• 16 Books

• 100 e-Proceedings/Tweet Collection

THAT does not include the other numbers of 1 to 13 above
THAT does not include NLP and Blockchain integration

#2 Ongoing Data Updates

Who will update the data stored in Blockchain with new items to be indexed as they become available

#3 Scaling Up

Example:

Running NLP on

• all articles in Research category “cell biology” will yield a

Hypergraph, hg1

• all articles on Cancer cell biology will yield a

Hypergraph, hg2

• all e-Proceeding on Cancer will yield a

Hypergraph, hg3

• Genomics volume 1 will yield a Hyper-graph, hg4

We need a DB for hg(1) to hg(n)
We need that Hyper-graphs will be stored in a DB of images – annotated and searchable Hyper-graphs AVAILABLE for download e-Readers needs to pay for the download Hyper-graphs were CREATE FROM PROPRIETARY Content, aka LPBI IP via Text Analysis on the CONTEXT OF THE CONTENT curated by experts defining What a sub-context is in a domain

Versus

Running NLP on PubMed content in the public domain searchable by date of publication, keyword in title and author name

IF we execute on Medical Text Analysis THEN

WHAT we have for monetization is NOT only

• IP Asset Class I (journal articles), II (e-Books), III (e-Proceedings), V (Image Gallery)

BUT

• all the RESULTS from 1 to 13 above minus numbers not related to NLP strategy.

Founder’s VISION Updated on 11/27/2020

Initiative #1:

One entry for WIKIPEDIA to be recreated in 1Q 2021

1.0 LPBI entry

2.0 LPBI entry

Founder of 1.0 LPBI and 2.0 LPBI – Aviva Lev-Ari, PhD, RN

Work-in-Progress

Initiative #2:

Planning & Launch of a New Web Site for 2.0 LPBI – work-in-progress

Website Design for the New Strategies (NS)

Two Site Map Proposals for LPBI’s New Web Site

Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/

Work to start by Gail, Aviva in December 2020

New SITE MAP under a newly to be selected WordPress.com Theme:

LPBI 2012-2025 – NEW WEB SITE for 2021 – 2025

OUR HISTORY

1.0 LPBI is our Current Website http://pharmaceuticalintelligence.com
Calling 4/2012 to 12/2020 (1.0 LPBI) – OUR HISTORY
It will become the BACK-END of the New Web Site, aka, 2.0 LPBI with a FRONT-END Interface

OUR FUTURE

2.0 LPBI – will be our NEW WEB SITE about 2021 and BEYOND
Work on the New WEBSITE to start in December 2020 by Gail, Aviva, Inbar

Site Map Version 1: Proposal by Aviva

2021-2025: 2.0 LPBI SITE MAP

2.0 LPBI:

Executive Summary
Brochure
Vision
Team’s Knowledge Portals System

PRODUCTS

Digital Text & Image Products

6,000 Articles
Article Abstract in WordClouds Images [2020 Summer Internship]
Gallery of +5,000 Biological Images

Audio Products:

Articles in SoundCloud files
Audio Books in Medicine
Biotech & Medical Conference e-Proceedings
Tweet Collections

BioMed e-Series Electronic Books in Foreign Languages

16 e-Volumes in Japanese
16 e-Volumes in Spanish
16 e-Volumes in Russian

SERVICES

AI/ML: Genomics & Cancer
Insights as a Service [IaaS]: 2021 Medical Text Analysis using NLP, ML, AI
Blockchain as a Service [BaaS]: Content Trade using Transactions System for a Digital Store on a Healthcare Marketplace functioning as an Exchange
e-Voices Podcasting
Drug Discovery using Synthetic Biology – JV
Customer Surveys

ABOUT

Testimonials
Board Members
Founder
Coronavirus Portal
Quarterly Newsletters
Current News
Calendar
Contact us

2012-2020: 1.0 LPBI SITE MAP

https://pharmaceuticalintelligence.com/

1.0 LPBI:

Executive Summary
Brochure
History
VISTA for Exit
Our Team of Contributors, 2012 – 2020
Investor Relations

Digital PRODUCTS

Journal PharmaceuticalIntelligence.com: 6,000 articles
BioMed e-Series: e-Books
Press Coverage: e-Proceedings
Social Media Coverage: Tweet Collections

Business SERVICES

Funding, Deals & Partnerships
Healthcare Investor’s Corner

ABOUT

Testimonials
Board Members
Founder
Coronavirus Portal
Quarterly Newsletters
Current News
Calendar
Contact us

@@@@@

Site Map Version 2: Proposal by Gail S. Thornton

Draft updated: 11/30/2020 Site Map Connect With Us Search Email LinkedIn Twitter Facebook

Leaders in Pharmaceutical Business Intelligence Group

Note: Our Company, Our Services, Our Commitment are major buckets in this order.

Our Company Our Services

About Us Pharmaceutical e-journal Leadership Board Members AI / ML: Genomics, Cancer Executive Team Biomed e-books History Audio and Foreign language books Locations Conference e-Proceedings Testimonials Podcasts Newsletters Coronavirus portal Medical text analysis Blockchain technology Calendar

Our Commitment

LPBI 2.0 Executive Summary Vision Brochure Knowledge Portals LPBI 1.0 Executive Summary Vision Brochure Summer Internship Program WordCloud article abstracts Drug Discovery Joint ventures Investor Relations Health care Investors’ Corner Customer Surveys

@@@@

Initiative #3:

2.0 LPBI Strategy: 2021 and Beyond

2.0 LPBI entry will cover the New Strategies: NS #1, #2, #3, #4, #5, #6

Strategy #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market by NLP applications.

AI-powered future

Machine learning, data mining, and statistical pattern recognition.
Supervised learning (parametric/non-parametric algorithms, support vector machines, kernels, neural networks).
Unsupervised learning (clustering, dimensionality reduction, recommender systems, deep learning)
Best practices in machine learning (bias/variance theory; innovation process in machine learning and AI).
Analyze language, uncover contextual patterns, and produce insights from text and audio.
Translate languages and summarize text

Phase 1: Natural Language Processing (NLP) – 12 months FREE Microsoft AZURE for Health

NO-GOING – Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed by LPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery
Inputs for Proof of Concept are the following three:

(1) Top 12 articles by views (all domains) (2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1 (3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1

Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:

Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2

Expand applications of Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
Application on the ingress TEXT from:

Series C: e-Books on Cancer & Oncology

Volume 1:

Cancer Biology and Genomics for Disease Diagnosis

http://www.amazon.com/dp/B013RVYR2K

Volume 2:

Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

http://www.amazon.com/dp/B071VQ6YYK

and

Series B: Frontiers in Genomics Research

Volume 1:

Genomics Orientations for Personalized Medicine

http://www.amazon.com/dp/B018DHBUO6

Volume 2:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

The Wolfram Solution for Biological Sciences
The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

LPBI Group’s FOUR Corpuses

(1) All 6,000 Journal Articles

(2) 16 Books in Medicine

(3) 60 e-Proceedings & 36 Tweet Collections of TOP Global Medical and Biotech Conferences, 2013 – 2020

(4) Content Segmentation by other criteria for Narrow casting the content of the journal ontology, Categories of Research (N = 715). About 70% are related to Drug Discovery

Strategy #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: a Partner had lined them up and are willing to build the Front End

Strategy #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

Strategy #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL

Strategy #5: Joint venture with Biotech Accelerator for Drug Discovery:

Strategy #6: e-Books Translations into Japanese, Spanish, Russian

Initiative #4:

New Industry Partnerships

2.0 LPBI: 2021 and Beyond

In Details – the New Strategies: NS #1, #2, #3, #4, #5, #6

A. Explorations with a Leader NLP Vendor in Healthcare

2.0 LPBI – NS #1: Text Analysis with NLP, ML, AI

Proof of Concept in Cancer and Genomics is been developed for a Top Healthcare Insurer in UT.

New cohort of INTERNS are joining LPBI on August 2020
Text Analysis using Microsoft AZURE, NLP for Health – was tested and abandoned
Proof of Concept will be design based on Text from the following THREE Sources and Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/07/21/wordcloud-visualization-of-lpbis-top-twelve-articles-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/ WordCloud Visualization of LPBI’s Top Sixteen Articles on CANCER in eight categories and by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curator: Stephen J. Williams, PhD and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD and Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/07/30/wordcloud-visualization-of-lpbis-top-sixteen-articles-on-cancer-in-eight-categories-and-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/ WordCloud Visualization of LPBI’s Top Sixteen Articles on GENOMICS by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curators: Stephen J. Williams, Aviva Lev-Ari, PhD, RN and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD https://pharmaceuticalintelligence.com/2020/07/30/wordcloud-visualization-of-lpbis-top-sixteen-articles-on-genomics-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/

B. Explorations with Blockchain Vendors in the Healthcare Sector

2.0 LPBI – NS #2: Blockchain Transaction Network Infrastructure – Partnership with World leader in the making.

The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections

Work to start after Proof of Concept will be completed and All INSIGHTS will be used to narrowcast the articles by Research Categories. Using 12 Word Clouds for word-smithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered per communities specialties and the Article Titles available for download for $30 each.
Front end design and narrow casting to Research Foundry and Communities on Partner’s Transaction System
Competitors in this space

In the Healthcare Sector

The top 10 competitors in Blockchain technology are:

AMC Health

Real-Time. Proven. Seamless.

AMC’s superior platform combines more than 17-years of hands-on clinical expertise, plus state-of-the-art technology providing real time patient data. Our platform is the only FDA Class II cleared care management platform, with multiple peer-reviewed studies and the ability to provide seamless connections that bridge the gap for care teams, members (patients) and payors.

https://www.amchealth.com/

Trapollo

Trapollo Converge

Secure, cloud-based, connected patient engagement — that extends care beyond the traditional walls of healthcare.

Trapollo Converge is a highly flexible and extensible virtual-care platform purpose-built for delivering care coordination and health monitoring. It provides intuitive and easy-to-use technology and a device-agnostic platform for clinicians, patients and family caregivers.

With its powerful digital engagement tools, telehealth capabilities and monitoring functions, Trapollo Converge connects its clients across the healthcare spectrum and patient populations to fulfill the true promise of Connected Health delivery.

https://www.trapollo.com/

Tactio Health Group

We digitize remote care for physician groups demanding scalable, secure and senior-friendly solutions.

We make RPM programs successful in North America with our pillar platform CareSimple, designed for physician groups of all sizes and their patients of any age. We also help integrate RPM solutions in other regulatory markets with CareSimple Franchise.

We build on the vast experience of over 4.5M Health App downloads in 17 languages, 100+ medical device integrations, and several prereimbursement RPM care models.

We strive to make our software and services simple so our customers can focus on care, patient compliance, clinical efficiency and outcomes.

We are collaborative and agile and we operate under the rigor of audited quality and security processes.

https://tactiohealth.com/

Vivify Health

Vivify Health is transforming healthcare by replacing episodic approaches with the market’s most complete, patient-centered, and holistic connected care platform. Discover how we can help you launch and scale comprehensive, effective remote care programs that create exceptional clinical and financial ROI for chronic and post-acute care as well as wellness management.

Setting patients in the right direction for a continued path towards a healthy life is Vivify Health’s main priority. Using Vivify Pathways (our Remote Care Platform), you can choose from over 90 clinical and engagement pathways or combine them into thousands of programs. We don’t have one you need? You can use our intuitive drag-and-drop portal to create your own.

Scheduling and automating patient encounters to connect, engage, educate, guide, monitor and intervene gives you a great pathway towards success.

Start a population (or single patient) on a simple pathway. Based on patient events… interventions, escalations, and even additional pathway content can be automatically engaged for a patient, keeping populations on the right path with much less manual effort.

https://www.vivifyhealth.com/

TELUS Health

Accessible healthcare

A term often used interchangeably with telemedicine, telehealth or virtual healthcare, virtual care is the process of providing 24/7 real-time access to medical professionals via a mobile device – by voice, text or video.

In addition to diagnosing and treating common primary care ailments, virtual care also provides access to a broader range of non-clinical care services, such as mental health support, chronic disease management, and even specialist referrals and prescriptions.

https://www.telus.com/en/health/about-telus-health

Vitalmobile Health

VitalMobile is a Portuguese company who develops its activity exclusively in Remote Telemonitoring, and was a world pioneer in Professional Patient Monitoring.

VitalMobile, a “Spin Off” of UltraPonto, invests since 2003 its resources in improving the quality of life of patients. By helping each patient to better understand their condition, and support caregivers by giving them access to biometric data in real time and distance, has developed and implemented a new health model with proven benefits.

This model helps to improve the sustainability of the National Health Service and the profitability of private health providers to make the monitoring more efficient, patient complying with medical protocols and ensuring significant reduction of operating costs, travel, management, work organization and their prioritization.

https://www.vitalmobile.eu/en/content/company

Ingeniumcare

INGENIUM HEALTHCARE ADVISORS is a team of seasoned Healthcare Delivery Improvement experts with healthcare experience ranging from 15 to 30 years.

Our ADVISORS enable providers to deliver the best care in the most efficient and cost-effective way.

We bring extensive experience in

– Project Management

– Business Analysis

– Quality Improvement

– Health IT

– Telehealth & Telemedicine

– Digital Health, Connected Health, and TeleHealth Strategy

We are Doctors, Nurses, Physician Assistants, Engineers, MBAs, and Healthcare Lawyers.

In partnership with forward-thinking healthcare leaders we develop Digital Health and Healthcare Delivery Improvement strategies. But we don’t stop there. We then implement the strategy by working with clinical, technical and administrative staff to design and build the unique solutions that improve the delivery of care.

Together we pursue one goal: Enabling Extraordinary Care.

https://ingeniumdigitalhealth.com/

Cardiocom, LLC

Medtronic, Inc. Drops $200 Million on Cardiocom LLC

Published: Aug 12, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Medtronic spends $200 million to acquire disease management company Cardiocom, the Wall Street Journal reports. Medtronic (NYSE:MDT) bought Cardiocom LLC for $200 million in cash in a bid to get into the disease management business, according to the Wall Street Journal. Chanhassen, Minn.-based Cardiocom makes devices aimed at helping to manage chronic conditions like diabetes or heart disease. The acquisition is aimed at putting Fridley, Minn.-based Medtronic in position to take advantage of the increasing focus on lowering healthcare costs, Medtronic’s U.S. president Mike Genau told the newspaper.

VSee Lab

About the VSee Team

We’re more than a telemedicine platform. We’re people who believe in the power of telemedicine to save money, save lives, and improve healthcare. Our mission is to make telehealth an everyday experience, and we’re committed to helping our partners succeed at this. VSee serves over 2000 clients including GE, Shell, Trinity, DaVita, McKesson, Optum and NASA Space Station.

In the Beginning…

VSee was founded in 2008 by two Stanford PhD students, Dr. Milton Chen and Dr. Erika Chuang. They wanted to change how we worked by making remote work simple. Dr. Chen did his PhD research on the psychology of video communications, and also coded the original VSee video application. Dr. Chen has the privilege to deploy VSee for former President Obama’s Inauguration, the Navy Seals, and notables such as former Secretary of State Hillary Clinton, former UN Secretary-general Ban Ki-moon, Angelina Jolie, and Linkin Park. Dr. Chen has also been on numerous humanitarian and medical missions trips, personally traveling to Iraq twice, Syria twice, as well as Africa, Southeast Asia, and Latin America on many occasions.

Today we are a global tribe of designers and engineers passionate about using our skills to make a difference in the healthcare space. Telemedicine shouldn’t be another EMR nightmare, and doctors don’t need more apps they won’t use. We’re here to create a telemedicine experience that’s as simple and accessible as shopping online. That’s what we’re all about.

https://vsee.com/

PROMINENT BLOCKCHAIN-AS-A-SERVICE PROVIDERS

Dragonchain
Factorm
Bloq
Skuchain
LeewayHertz
Altoros
Appinventiv
Fluence
Innominds

SOURCE

https://builtin.com/blockchain/blockchain-as-a-service-companies

Competitors in Blockchain specializing in Healthcare include the following:

BurstIQ

Total Funding$6 M

BurstIQ’s data and cyber security services are focused on minimizing and managing the security risk that all health organizations face. Our practice area expertise includes mobile security, Cloud security, managed security services, policy and compliance, threat assessments, and digital forensics. We are able to address all aspects of the data security life cycle to include initial threat and solution assessments, solution design, implementation, and ongoing operations.Show more

Type	Private
Founded	2015
HQ	Colorado Springs, US	Map
Website	burstiq.com

BurstIQ Launches Full Developer Toolset for Blockchain-Enabled Applications and Services
PR Newswire19 Aug 2020
Hitachi, the American Heart Association, and BurstIQ launch COVID-19 Data Challenge
VentureBeat12 May 2020
BurstIQ and Partners Launch Collaborative Research Coalition to Tackle COVID-19 and other Global Health Crises
PR Newswire08 Apr 2020

Employees (est.) (Oct 2020)	29	(-3%)
Cybersecurity rating	B	More

Indegene Lifesystems HQ Princeton, US Employees 2,378↑ 2% increase We help healthcare organizations address complex challenges by seamlessly integrating Analytics, Technology, Operations and Medical expertise. View company Doctify HQ London, GB Employees 50↓ 4% decrease Doctify is a company operating an online platform that connects patients with the doctors. View company Entopsis HQ Medley, US Employees 10↓ 9% decrease We are a young and driven biotech startup team based in Miami, Florida. Our aim is to create a cost-effective platform for regular health monitoring. View company Avalon AI HQ London, GB Employees 1 Avalon AI is a company focusing on the automated derivation of brain biomarkers. View company

SOURCE

https://craft.co/burstiq/competitors https://builtin.com/blockchain/blockchain-healthcare-applications-companies

C. Explorations with New Audio & Video Technologies for Podcasting

2.0 LPBI – NS #3: Audio-Video Podcasts Library

Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina

Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond

D. Explorations with Text to Audio Vendors

2.0 LPBI – NS #4: Conversion of LPBI’s e-Book Series into 16 AUDIO BOOKS and

Text to Audio for each Article (N = 6,000)

Strategy will be presented on August 18, 2020 Zoom Monthly Meeting

E. Explorations with Synthetic Biology for Drug Discovery

2.0 LPBI – NS #5: Joint Venture : 2.0 LPBI (30%) and Biotech Accelerator (70%)

President of the Biotech Accelerator had proposed on 7/21/2020: https://pharmaceuticalintelligence.com/calendar/

Usage of Lab Space and Services of ABI LAB for the purpose of:
Synthetic Biology Research on Galectins, See Table, below
2.0 LPBI Research Team: Ofer Markman, PhD and Irina Robu, PhD and Meg Baker, PhD

F. Explorations with Translation Agencies in Foreign Languages

2.0 LPBI – NS #6: e-Books Translations into Japanese, Spanish, Russian

Plan will be developed in 2021

More Details on 2.0 LPBI’s the New Strategies:

NS #1, #2, #3, #4, #5, #6

That section will be updated upon FINAL VENDOR SELECTION

NS #1: Text Analysis with NLP, ML, AI

THE PLAN; 4Q 2020 & 2021

NS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Phase 1: Natural Language Processing(NLP) – 12 months FREE Microsoft AZURE for Health

explored ans abandoned

Different NLP Vendor in the run

Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed byLPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery
Inputs for Proof of Concept are the following three:

(1) Top 12 articles by views (all domains) (2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1 (3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1

Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:

Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2

Expand applications of Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
Application on the ingress TEXT from:

Series C: e-Books on Cancer & Oncology

Volume 1:

Cancer Biology and Genomics for Disease Diagnosis

http://www.amazon.com/dp/B013RVYR2K

Volume 2:

Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

http://www.amazon.com/dp/B071VQ6YYK

and

Series B: Frontiers in Genomics Research

Volume 1:

Genomics Orientations for Personalized Medicine

http://www.amazon.com/dp/B018DHBUO6

Volume 2:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

The Wolfram Solution for Biological Sciences
The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

LPBI Group’s FOUR Corpuses

(1) All 6,000 Journal Articles

(2) 16 Books in Medicine

(3) 60 e-Proceedings & 36 Tweet Collections of TOP Global Medical and Biotech Conferences, 2013 – 2020

(4) Content Segmentation by other criteria for Narrow casting the content of the journal ontology, Categories of Research (N = 715). About 70% are related to Drug DIscovery

The Voice of Ofer Markman, PhD

In 2020 and beyond, 2.0 LPBI brings to the Table:

An Interdisciplinary Team of Experts

Deep Multiple Domains Knowledge

Academic and Industry Recognition

Remarkable e-Reputation on leading professional social media platforms, i.e., Twitter.com (The Leader for BioSciences Innovations announcements) and LinkedIn.com

Global Expansive Business Connections

Record of Unmatched Execution & Leadership

Dr. Ofer Markman

Work to continue by All ACTIVE FIT Members in their expertise and ALL the INTERNS: current & new
Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications
Using Microsoft AZURE – NLP for Health for the Proof of Concept
For Cancer Volume 1 & 2 and Genomics Volume 1 & 2 – Comparison of Microsoft AZURE for Health with Text Analysis The Wolfram Language

On July 24, 2020, Dr. Williams on Methods to Improve the WordCloud images:

“So my suggestion would be actually to focus on the little words, which will give more insight into future targets, as the large words are well known. For example AKT, PI3K cancer is very well studied and dominates the literature. However, looking at some of the lesser ones, siRNA, targeting ,nuclear, complex, breast, targeted can one form into logical sentences which describe new avenues for research?” Also with the Word loud in media gallery readers can see a high definition image of it and then you can edit. Editing needs be done while on WordItOut.com platform before saved and exported.

On Sat, 8 Feb 2020 at 15:22 Aviva Lev-Ari <aviva.lev-ari@comcast.net> wrote:

UPDATED on 7/19/2020

The concept of HyperGraphDB and set of rules are needed to be created for the 1400 curations of Dr. Larry, more than half are about signaling pathways used in therapeutics using receptors.

THEN we will have the software for auto-independent semantic Text analysis of Dr. Larry’s UNIVERSE of articles – this was Dr. Williams great Idea.

(7/19/2020 – 5,875 (all articles) / 1400 (LHB’s Universe = 23.8%) of our IP in Journal articles.

Please read below, article and send me your comment on its relevance to our current search for a Partner with expertise in Machine Learning, Natural Language Processing, AI for text analysis.

https://www.wired.com/story/code-obsessed-novelist-builds-writing-bot-the-plot-thickens/

Example

Akt inhibition for cancer treatment, where do we stand today?

Article #11: WordCloud by DM

NS #2: Blockchain Infrastructure – The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections

15 EXAMPLES OF HOW BLOCKCHAIN IS REVIVING HEALTHCARE

Sam Daley

July 1, 2019

Updated: March 25, 2020

https://builtin.com/blockchain/blockchain-healthcare-applications-companies

BURSTIQ
Industry: Big Data, Cybersecurity, Software
Location: Colorado Springs, Colorado
What they do: BurstIQ’s platform helps healthcare companies safely and securely manage massive amounts of patient data. Its blockchain technology enables the safekeeping, sale, sharing or license of data while maintaining strict compliance with HIPAA rules. Blockchain application: The company uses blockchain to improve the way medical data is shared and used. Real-life impact: Because BurstIQ’s platform includes complete and up-to-date information about patients’ health and healthcare activity, it could help to root out abuse of opioids or other prescription drugs.
FACTOM
Industry: IT, Enterprise Software
Location: Austin, Texas
What they do: Factom creates products that help the healthcare industry securely store digital records on the company’s blockchain platform that’s accessible only by hospitals and healthcare administrators. Physical papers can be equipped with special Factom security chips that hold information about a patient and stored as private data that is accessible only by authorized people. Blockchain application: Factom employs blockchain technology to securely store digital health records. Real-life impact: In June of 2018, Factom got a grant of nearly $200,000 from the U.S. Department of Homeland Security to beta-test a platform aimed at integrating secure data from Border Patrol cameras and sensors in order to better understand the impacts of blockchain in “a realistic field environment.”
MEDICALCHAIN
Industry: Electronic Health Record, Medical
Location: London, England
What they do: Medicalchain’s blockchain maintains the integrity of health records while establishing a single point of truth. Doctors, hospitals and laboratories can all request patient information that has a record of origin and protects the patient’s identity from outside sources. Blockchain application: Medicalchain’s blockchain-based platform maintains a record of origin and protects patient identity. Real-life impact: In May of 2018, Medicalchain announced the release of MyClinic.com. A telemedicine platform, MyClinic enables patients to consult with their doctors via video and pay for those consultations with “MedTokens.”
GUARDTIME
Industry: Cybersecurity, Blockchain
Location: Irvine, California
What they do: Guardtime is helping healthcare companies and governments implement blockchain into their cybersecurity methods. The company was vital in helping implement blockchain in Estonia’s healthcare systems, and it recently signed a deal with a private healthcare provider in the United Arab Emirates to bring blockchain to its data privacy systems. Blockchain application: Guardtime employs blockchain for cybersecurity applications, including healthcare. Real-life impact: Guardtime recently teamed with Verizon Enterprise Solutions to deploy several platform services based on Guardtime’s Keyless Signature Infrastructure (KSI) Blockchain.
SIMPLYVITAL HEALTH
Industry: AI, Blockchain, Enterprise Software, Personal Health
Location: Watertown, Massachusetts
What they do: SimplyVital Health is making its decentralized technology available to the healthcare industry. It’s Nexus Health platform is an open source database that allows healthcare providers, on a patient’s blockchain, to access pertinent information. Open access to important medical information helps healthcare professionals coordinate medical efforts more quickly than traditional methods. Blockchain application: SimplyVital uses blockchain to create an open source database so healthcare providers can access patient information and coordinate care. Real-life impact: SimplyVital recently partnered with genemics and precision medicine company Shivom to form a Global Healthcare Blockchain Alliance that employs blockchain security to protect DNA sequencing data.
CORAL HEALTH RESEARCH & DISCOVERY
Industry: Healthcare, IT
Location: Vancouver, Canada
What they do: Coral Health uses blockchain to accelerate the care process, automate administrative processes and improve health outcomes. By inserting patient information into distributed ledger technology, the company connects doctors, scientists, lab technicians and public health authorities quicker than ever. Coral Health also implements smart contracts between patients and healthcare professionals to ensure data and treatments are accurate. Blockchain application: Coral’s blockchain technology accelerates care, automates administrative processes and employs smart contracts between patients and doctors. Real-life impact: According to Coral’s chief strategy officer Jeremy Mullin, the company is looking into the possibility of using a blockchain and the Smart on FHIR protocol “to let patients track their own health files.”
ROBOMED
Industry: Blockchain, Medicine
Location: Moscow, Russia
What they do: Robomed combines AI and blockchain to offer patients a single point of care. The company deploys chatbots, wearable diagnostic tools and telemedicine sessions to gather patient information and share it with the patient’s medical team. Robomeds Panacea platform engages patients into smart contracts that incentivize and lead them down the path to better health. Blockchain application: Robomed uses blockchain to securely gather patient information and share it with a patient’s healthcare providers. Real-life impact: The Taipei Medical University Hospital recently implemented blockchain technology, including Robomed’s network, to more securely store and share medical records.
PATIENTORY
Industry: Blockchain, Cybersecurity, Healthcare, IT
Location: Atlanta, Georgia
What they do: Patientory’s end-to-end encryption ensures that patient data is shared safely and efficiently. The company’s platform enables patients, healthcare providers and clinicians to access, store and transfer all important information via blockchain. Patientory helps the healthcare industry to move more quickly by housing all patient information under one roof. Blockchain application: Patientory’s blockchain platform enables the secure storage and transfer of important medical information. Real-life impact: Patientory recently hosted its first North American Blockchain in Healthcare Summitthat gathered hundreds of healthcare professionals to discuss and learn about blockchain-based healthcare applications.
CHRONICLED
Industry: Blockchain, Supply Chain Management
Location: San Francisco, California
What they do: Chronicled builds blockchain networks that demonstrate chain-of-custody. The networks help pharma companies make sure their medicines arrive efficiently, and they enable law enforcement to review any suspicious activity — like drug trafficking. In 2017, Chronicled created the Mediledger Project, a ledger system dedicated to the safety, privacy and efficiency of medical supply chains. Blockchain application: Chronicle’d blockchain network is used to ensure the safe arrival and detailed review of drug shipments. Real-life impact: According to the company, results from Chronicled’s recent MediLedger Project prove that its blockchain-based system “is capable of acting as the interoperable system for the pharmaceutical supply chain” and “can meet the data privacy requirements of the pharmaceutical industry itself.”
BLOCKPHARMA
Industry: Blockchain, Pharmaceuticals, Supply Chain
Location: Paris, France
What they do: Blockpharma offers a solution to drug traceability and counterfeiting. By scanning the supply chain and verifying all points of shipment, the company’s app lets patients know if they are taking falsified medicines With the help of a blockchain-based SCM system, Blockpharma weeds out the 15% of all medicines in the world that are fake. Blockchain application: Through its app, the company’s blockchain-based system can help prevent patients from taking counterfeit medicines.
TIERION
Industry: Saas, Blockchain
Location: Mountain View, California
What they do: Tierion’s blockchain audits documents, records and medicines to keep a clear history of possession. The company uses timestamps and credentials to maintain proof of ownership throughout a medical supply chain. Blockchain application: The company uses blockchain to maintain a clear possession history within medical supply chains. Real-life impact: Tierion recently proposed a “multi-network coin” that could make Bitcoin more versatile and applicable.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
Industry: Government Agency, Healthcare, Security
Location: Atlanta, Georgia
What they do: The Centers for Disease Control and Prevention is looking into blockchain to monitor diseases in a supply chain-like manner. The U.S. Government agency says blockchain’s timestamps, peer-to-peer health reporting and data processing capabilities can help report disease outbreak in real-time. By studying the trail of reported outbreaks, scientists can find the origin of a disease and patterns that help suppress disease. The CDC might also employ blockchain to track the opioid epidemic. Blockchain application: The CDC uses blockchain to monitor diseases and report outbreaks in real time. Real-life impact: IBM is working with the CDC to develop a blockchain-based surveillance system so public health agencies can more effectively gather data about patients and prescriptions.
NEBULA GENOMICS
Industry: Biotechnology, Genetics
Location: Boston, Massachusetts
What they do:Nebula Genomics is using distributed ledger technology to eliminate unnecessary spending and middlemen in the genetic studying process. Pharmaceutical and biotech companies spend billions of dollars each year acquiring genetic data from third parties. Nebula Genomics is helping to build a giant genetic database by eliminating expensive middlemen and incentivizing users to safely sell their encrypted genetic data. Blockchain application: The company uses blockchain to streamline the study of genetics and lower costs.
ENCRYPGEN
Industry: Blockchain, Data-Sharing
Location: Coral Springs, Florida
What they do: The EncrypGen Gene-Chain is a blockchain-backed platform that facilitates the searching, sharing, storage, buying and selling of genetic information. The company protects its users’ privacy by allowing only other members to purchase the genetic information using safe, traceable DNA tokens. Member companies can use the genetic information to build upon their genetic knowledge and advance the industry. Blockchain application: The company’s blockchain platform makes it easier to search for, share, store and buy genetic information. Real-life impact: EncrypGen plans to expand its user profile to include self-reported medical and behavioral data. According to company co-founder and CEO Dr. David Koepsell, it’s also working on integrating a blockchain payment and auditing platform as well as forming partnerships with testing companies, analytics software developers and others.

DOC.AI
Industry: AI, Blockchain, Medical, Software
Location: Palo Alto, California
What they do: Doc.ai uses machine intelligence, like AI, to decentralize medicine on the blockchain. Users can opt into the company’s platform to share their medical and genomic data with a community of scientists that use the data for predictive modeling. doc.ai saves no patient data. Once information is uploaded, encrypted on a blockchain and used in a trial, the data is wiped out in order to ensure security and privacy. Blockchain application: The company’s employs machine intelligence (like AI) to decentralize medical data on the blockchain. Real-life impact: The company recently partnered with health insurer Anthem tostudy the use of artificial intelligence in predicting the occurrence of allergic reactions.
RELATED

Healthcare Technology: What It Is + How It’s Used

LinkedIn Hacker News Reddit Twitter Facebook

SOURCE

https://builtin.com/blockchain/blockchain-healthcare-applications-companies

Work to start upon completion of the Proof of Concept

Using 12 Word Clouds for word-smithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered and the Article Titles available for download for $30 each.

We wish to monetize the IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V
Foundry Research is the community of Scientists built by a Partner – they had presented on 7/21 at 3PM EST

The Voice of Stephen J. Williams, PhD, CSO, 1.0 LPBI

sjwilliamspa

The concept of combining HyperPad, WordCloud, and mind-mapping could be a powerful tool (or platform) in conjunction with a corpus of knowledge, i.e.,

Dr. Bernstein’s sub corpus of knowledge here or

Dr. Fauci’s corpus of knowledge obtained from Pubmed) then one can

Maps the Mind of any KOL in any given area

sjwilliamspa

The ability of blockchain technology to offer secure, ledgered, and recorded transfer of data has only started to be utilized for literature, although mainly for transfer of secure electronic records involving healthcare records or business and legal documents.

The use of blockchain for the secure, ledgered transfer/access to biomedical literature would be a novel undertaking. This type of technology would enhance legitimate transfer of data (articles) [a chief goal of 2.0 LPBI] while preventing the illegitimate transfer of those articles by data trollers.

This could actually enhance the mission of 2.0 LPBI to rapidly and openly disseminate information. Blockchain will also allow better data management more under the control of an entity which own the corpus and allow analysis in real time by third party algorithms, given access through blockchain of said corpus (Agora of knowledge).

Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case StudiesCurator and Editor-in-Chief: Journal and BioMed e-Series, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/ In addition,

blockchain may assist in ways to incentivize the creators of knowledge in a sort of a self sustaining ecosystem. This has been tried by many open access journals where reviewers for the journal are given credits to defray publication costs

therefore Value of Effort = monetized Value ($)

this maintains the integrity of effort, the integrity of work and actually enhances it.

Through blockchain technology this can run automated and unbiased.

The Voice of Daniel Menzin:

“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V”

1. Blockchain may be able to provide us with an organized way to keep track of each 30 dollar transaction. I would imagine their system would provide us with useful data as well which we can analyze like we’ve done with Twitter and WordPress.

2. Since Blockchain is a shared ledger, it can distribute data across sites, institutions, or countries. This would allow us to organize all of our IP assets and transact with our buyer digitally, requiring less work to be done by the buyer in developing our existing infrastructure for their purposes I would imagine.

3. It appears to me that Blockchain would improve the efficiency and ability to track our business transactions and documentation during our exit process. Blockchain claims to provide a shared digital medium for tracking the paperwork and agreements existing between two business parties. It is a shared, immutable ledger meaning that “it is a consensus of replicated, shared, and synchronized digital data geographically spread across multiple sites, countries, or institutions. Unlike with a distributed database, there is no central administrator.” It is immutable, meaning that the data cannot be changed once a consensus is reached (to my understanding). It seems like an automated digital system which serves to improve the organization and efficiency of business transactions by creating “a system” of sorts which organizes information related to these processes.

The Voice of Aviva Lev-Ari, PhD, RN:

“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI IP Asset Classes:

I (Journal),
II (e-Books),
III (e-Proceedings+Tweet Collections),
IV (Composition of Methods),
V (Gallery of Biological Images)

These resources [1.0 LPBI: IP Asset Classes I, II, III, IV, V] could be accessed on a National level (Country x,y,z) or at the EU level or another geography (South East Asia) by

All Life Science Incubators
All Biotech Start ups
All Life Sciences Departments in any Higher EducationInstitute
All Medical Schools: Faculties using the content for curriculum development, Research Staff and Medical Students
All High school students writing Honor Final thesis in Life Sciences
All private individuals seeking knowledge in the Life Sciences & Medicine, Pharmaceutics and Health Care
Private & Public interests can be served: the Biotech/Healthcare sectors, Education Sectors, and
it can in parallel have a few business lines that are fully commercial for parties beyond Country x,y,z or the EU or another geography, i.e., Global and International NGOs such as Teva, IBM, GE Health, Siemens Healthineers, National’s HMOs can use the platform for Medical Doctors and Allied Health professionals continuing education using the contents of each of the three IP asset classes.

1. Blockchain may be able to provide us with a platform to narrowcast Word Cloud Images of

1.0 LPBI Journal Articles to the Research Foundry Community: Article Title (Live Link), Views, Categories of Research and Word Cloud Images

A platform for selling Journal Articles, Books, e-Proceedings and Tweet Collections

A Global Transaction System (GTS) generating Account Receivables and an Immutable ledger

2. 2.0 LPBI may be using Blockchain platform for the following functions:

Personalized Medicine,

Workflow Optimization,

High-Accuracy of 2.0 LPBI Article Buyer Directories,

Collaborative Research,

E-ID Programs,

National health Record Networks,

Health Information Exchanges,

Enterprise Data Networks,

Eligibility & Revenue Cycle,

Innovation Sandboxes,

Digital Therapeutics,

Reporting on Clinical Research

3. 2.0 LPBI may be using Blockchain platform for NARROWCASTING content to Partners and Communities that a Leader in Blockchain Platforms specializing in Health Care had already put in place.

We will narrowcast the Article WordClouds instead of the Article Abstracts, 12 examples are as presented below

We will narrowcast the electronic Table of Contents (eTOCs) instead of the the Preface

We will narrowcast the Tweet Collections to trigger interest in the entire e-Proceedings of a Conference

NS #3: Audio-Video Podcasts Library

Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina

Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond

Gail’s work:

Selected Projects:

1. Podcast Schedule https://pharmaceuticalintelligence.com/audio-podcasts/

Development Plan for e-VOICES Podcasting, 2019 – 2021*

https://pharmaceuticalintelligence.com/audio-podcasts/

Podcast Interviewer	INTERVIEWEE(S)	Subject	Date	Audio/Video/ Narrator

Gail S. Thornton	Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari	3D BioPrinting in Medicine	5/2019	Audio
Gail S. Thornton	Prof. Feldman	Evolution Biology and Population Genetics	3/17/2020	Audio
Gail S. Thornton	Dr. Larry H. Bernstein, MD, FCAP	Life Memoirs in Clinical Pathology Told	10/12/2020	Audio Narrator: Dr. S.J. Williams
Gail S. Thornton	Dr. Sudipta Saha	Research in Reproductive Technology	11/7/2020	Audio

Gail S. Thornton	Dr. Justin D. Pearlman, MD, PhD	Cardiac Imaging – Evolution of Diagnostic Methods	4Q 2020	Audio
Gail S. Thornton	Dr. Raphael Nir	From Big Pharma to Biotech Entrepreneurship	2021	Audio
Gail S. Thornton	Dr. Meg Baker	GlycoBiology in Practice	2021	Audio
Gail S. Thornton	Dr. Ofer Markman	Memories of Procognia	2021	Audio
Gail S. Thornton	Dr. Irina Robu	AI & Tissue Engineering	2021	Audio
Gail S. Thornton	Dr. Williams	Preferably 3^rd party interviewer sourced AI & Genomics by Gail	2021	Audio
Gail S. Thornton	Dr. Aviva Lev-Ari	Preferably 3^rd party interviewer sourced Curation & ML by Gail	2021	Audio

Interview with Professor Marcus Feldman, Stanford University by Gail S. Thornton

https://pharmaceuticalintelligence.com/audio-podcasts/

Forthcoming

Gail’s Interview with Dr. Larry H. Bernstein, MA, FCAP

A Narrated Version – Tribute to his life long Contributions to Medicine
LHB lost his voice in thyroid cancer in 2016, since then on Medical LEAVE @LPBI as CSO and Emeritus, Board Member

and

On 3/12/2015 – Dr. Williams posted

Podcast Review: Quiet Innovation Podcast on Obtaining $ for Your Startup

Reporter: Stephen J. Williams, Ph.D.

https://pharmaceuticalintelligence.com/2015/03/12/podcast-review-quiet-innovation-podcast-on-obtaining-for-your-startup/

On 1/25/2016 – Aviva posted

Launching LPBI’s, Fourth Line of Business (D): FIVE Podcast – Audio Series in BioMed

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

On 3/17/2016 – Aviva posted

CRISPR: A Podcast from Nature.com on Gene Editing

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/03/17/crispr-a-podcast-from-nature-com-on-gene-editing/

NS #4: Conversion of LPBI’s e-Book Series into AUDIO BOOKS

Strategy will be pursued in 2021

NS #5: Joint Venture : 2.0 LPBI and a Biotech Accelerator

President of the Biotech Accelerator proposed on 7/21/2020:
https://pharmaceuticalintelligence.com/calendar/

Usage of Lab Space and Services of the Accelerator for the purpose of:

Synthetic Biology Research on Galectins

2.0 LPBI Research Team: Ofer Markman, PhD and Irina Robu, PhD and Meg Baker, PhD

Scientists love Synthetic Biology – designing drug molecules using Software – igem.org
https://igem.org/Software A repository of open source software tools. Community driven data exchange standards. Specific software frameworks built explicitly for synthetic biology.

INTERNS are joining after Labor Day – they need to gain some LAB Flavor in return for working as Volunteers @LPBI projects: SEE

2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates

ABSTRACT

Galectins are carbohydrate-binding proteins that are involved in many physiological functions, such as inflammation, immune responses, cell migration, autophagy and signalling. They are also linked to diseases such as fibrosis, cancer and heart disease. How such a small family of only 15 members can have such widespread effects remains a conundrum. In this Cell Science at a Glance article, we summarise recent literature on the many cellular activities that have been ascribed to galectins. As shown on the accompanying poster, these include carbohydrate-independent interactions with cytosolic or nuclear targets and carbohydrate-dependent interactions with extracellular glycoconjugates. We discuss how these intra- and extracellular activities might be linked and point out the importance of unravelling molecular mechanisms of galectin function to gain a true understanding of their contributions to the physiology of the cell. We close with a short outlook on the organismal functions of galectins and a perspective on the major challenges in the field.

Table of Human Galectins [edit]

https://en.wikipedia.org/wiki/Galectin#Table_of_Human_Galectins

Human galectin	Location	Function	Implication in disease
Galectin-1	Secreted by immune cells such as by T helper cells in the thymus or by stromal cells surrounding B cells ^[7]Also found in abundance in muscle, neurons and kidney^[1]	Negatively regulate B cell receptor activationActivate apoptosis in T cells^[6] Suppression of Th1 and Th17 immune responses^[7] Contributes to nuclear splicing of pre-mRNA^[23]	Can enhance HIV infectionFound upregulated in tumour cells
Galectin-2	Gastrointestinal tract ^[24]	Binds selectively to β-galactosides of T cells to induce apoptosis^[24]	None found
Galectin-3	Wide distribution	Can be pro- or anti-apoptotic (cell dependent)Regulation of some genes including JNK1 ^[7] Contributes to nuclear splicing of pre-mRNA^[23] Crosslinking and adhesive properties In the cytoplasm, helps form the ULK1-Beclin-1-ATG16L1-TRIM16 complex following endomembrane damage^[13]	Upregulation occurs in some cancers, including breast cancer, gives increased metastatic potentialImplicated in tuberculosis defense^[13]
Galectin-4	Intestine and stomach	Binds with high affinity to lipid rafts suggesting a role in protein delivery to cells^[7]	Inflammatory bowel disease (IBD)^[7]
Galectin-7	Stratified squamous epithelium^[7]	Differentiation of keratinocytesMay have a role in apoptosis and cellular repair mediated by p53^[7]	Implications in cancer
Galectin-8	Wide distribution	Binds to integrins of the extracellular matrix.^[3] In the cytoplasm, alternatively binds to mTOR or forms the GALTOR complex with SLC38A9, LAMTOR1, and RagA/B^[12]	Downregulation in some cancersImplicated in tuberculosis defense
Galectin-9	KidneyThymus^[6] Synovial fluid Macrophages	Functions as a urate transporter in the kidney ^[25]Induces apoptosis of thymocytes and Th1 cells^[6]^[7] Enhances maturation of dendritic cells to secrete inflammatory cytokines. In the cytoplasm, associates upon lysosomal damage with AMPK and activates it^[12]	Rheumatoid arthritisImplicated in tuberculosis defense^[12]^[26]
Galectin-10	Expressed in eosinophils and basophils	Essential role in immune system by suppression of T cell proliferation	Found in Charcot Leyden crystals in asthma
Galectin-12	Adipose tissue	Stimulates apoptosis of adipocytesInvolved in adipocyte differentiation^[7]	None found

UPDATED on 1/6/2020 CURATIONS of Scientific basic research findings and clinical interpretation by EXPERTS —>> Curations were what LPBI Group created since 4/2012 —>> Curations are the value we bring to a potential acquirer in the Life Sciences, Medicine, pharmaceutical domain. —>> We did it in three channels for knowledge dissemination OF OUR COLLABORATIVE formulations: 1. One Article Format of Curation by Experts was replicated by collaborations with other team members >5,700 TIMES 2. Expert Editors created electronic Table of Contents (eTOCs) for our 1st e-Book published 6/2013. We REPLICATED the process on eTOCs creation by Expert Editors SIXTEEN TIMES, 12/28/2019, last volume placed on the Medicine & Life Sciences in Kindle Store – our Genomics Volume 2 on AI in Medicine 3. 4/2013 was first BioIT Aviva covered in real time and created the first e-Proceedings, Dr. Williams created Twitter Analytics for it, WE IMPROVED AND REPLICATED this process >60 TIMES

These three CORPUSES are seeking Transfer of Ownership and monetization in 2020.

NS #6: e-Books Translations into Japanese, Spanish, Russian

Plan for 2021 TBD

@@@@@ – OLD CONTENT

UPDATED on 11/18/2019 The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation https://pharmaceuticalintelligence.com/2019/07/31/the-digital-age-gave-rise-to-new-definitions-new-benchmarks-were-born-on-the-world-wide-web-for-the-intangible-asset-of-firms-reputation-pay-a-premium-for-buying-e-reputation/ For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets https://pharmaceuticalintelligence.com/2019/08/06/twitter-analytics-engagement-rate-link-clicks-retweets-likes-replies-tweet-highlights-tweets-impressions-profile-visits-mentions-new-followers-for-aviva1950-founder-lpbi-group-ph/

UPDATED on 7/23/2019

Founder’s Vision

Dr. Aviva Lev-Ari, PhD, RN is an alumna of University of California, Berkeley, PhD’83. Dr. Lev-Ari was nominated for the 2019 Alumni of the Year Award followed by 2020 Campanile Excellence in Achievement Awards nomination forthcoming, 11/2019. August 2018-July 2021, Dr. Lev-Ari serves the Massachusetts Academies of Sciences (MAS) as Liaison to the Biotechnology and eScientific Publishing industries. She serves as Board member, Fellow, and Advisor to the Governing Board http://www.maacadsci.org. LPBI Group as a venture was launched in 4/2012 by Dr. Lev-Ari and she is leading it since its inception. These significant accomplishments were achieved in

Pharmaceutical (Biomed e-Series, 16 volumes in the frontiers of Life Sciences and Medicine, average volume size: 2,400 pages, 96,000 page downloads),

Media (e-Proceedings of Biotech Conferences, 70 events covered, 2013 to Present) and

electronic Scientific Publishing (Open Access Online Scientific Journal, 1.7 Million readers, ~5,700 articles)

The growth in all the three domains, above, took place during that period and led to her nomination for the 2018 Yidan Prize. [Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/] Dr. Aviva Lev-Ari is the Director and Founder of a pharmaceutical media and digital scientific publishing group called Leaders in Pharmaceutical Business Intelligence (LPBI) Group, which owns the intellectual property in three interrelated healthcare content products:

IP Asset Class I.An on-line open access pharma scientific journal which has published about 5700 articles which have been read by over 1 1/2 million readers (1,640,034 as of 7/1/2019). http://pharmaceuticalintelligence.com

IP Asset Class II.A series of 16 e-books in five medical specialities, including cardiovascular, genomics, cancer, immunology and precision medicine – these are available on Amazon https://lnkd.in/ekWGNqA

IP Asset Class III. An electronic corpus of the proceedings of 70 top Global Biomed scientific and Medical conferences. https://pharmaceuticalintelligence.com/press-coverage/

These three IP Asset Classes represent a vast IP portfolio owned by LPBI Group. We are currently exploring in North America, Europe and Southeast Asia, prospective acquisition opportunities for these IP resources [vast content, digital printed products, platform, methods, methodologies and systems]. A prospective acquirer would be an establishment, a corporation or an institute that will be able to carry these IP resources forward under new ownership and new management, as a new company. Following the knowledge transfer phase, the current team can continue pursuing their expertise under the new ownership and the new management. This is a concept of an M&A. Alternatively, a sale outright of the portfolio of IP could be considered under certain terms and conditions. It is Dr. Aviva Lev-Ari’s belief that this newly to be established organizational entity would provide employment to dozens of Postdocs in the Life Sciences, who face a small number of Academic openings in the LIfe Sciences in the developed countries. It will attract Medical Doctors interested in writing clinical interpretations to basic life sciences primary research outcomes using the methodology of curation for scientific findings developed by Dr. Lev-Ari and her Team as demonstrated in the 5,700 articles in the Journal mentioned above which to date had attracted ~8000 comments by Scientist eReaders around the Globe using in search the +10,000 tags and the 670 categories of research which form the Ontology of the Journal. Following such a transaction, these three vast IP assets will be hosted on a Cloud Web Services platform architecture managed by the new ownership and offering to the Public the advantages of global accessibility [under terms and conditions]. These resources could be accessed on a National level (Country x,y,z) or at the EU level or another geography by

All Life Science Incubators

All Biotech Start ups

All Life Sciences Departments in any Higher EducationInstitute

All Medical Schools: Faculties using the content for curriculum development, Research Staff and Medical Students

All High school students writing Honor Final thesis in Life Sciences

All private individuals seeking knowledge in the Life Sciences & Medicine, Pharmaceutics and Health Care

Private & Public interests can be served: the Biotech/Healthcare sectors, Education Sectors, and

it can in parallel have a few business lines that are fully commercial for parties beyond Country x,y,z or the EU or another geography, i.e., Global and International NGOs such as Teva, IBM, GE Health, Siemens Healthineers, National’s HMOs can use the platform for Medical Doctors and Allied Health professionals continuing education using the contents of each of the three IP asset classes.

Human Capital and the Content Creation Process

The two Board Members, Dr. Stephen J. Williams and Dr. Marcus W. Feldman are fully involved in venture’s decision making activities.

The LPBI Group’s team members are all Experts, Authors, experienced Writers professing the Curation methodology applied for content creation in Translational Medicine from Life Sciences to bedside Medicine, Genomics, Bioinformatics, AI in Radiology and Pathology and Precision Medicine, Cancer, Cardiovascular diseases and Cardiac Imaging, Immunology, Infectious diseases, BioMedicine, Biotechnology, Pharmaco-therapy, Medical Technology and Health Care.

In House Business and Management Tool Development

The LPBI Group’s Business Team had developed an extensive business plan for the potential acquirers of these three IP asset classes. Twelve industries were identified. The Business Plan and the Opportunities Map are ready for perusal.

https://pharmaceuticalintelligence.com/2019-vista/

Full documentation of Intangible and of Tangible assets is updated quarterly.

2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis

The team developed a calculator for valuation of LPBI Group’s IP by contributing factors to value creation [in beta phase: IP-VAL-CALC]

The Opportunities Map, the Business plan and a detailed document describing the technology and the pipeline of new products and Content as a Service (CAAS), all three can be used for design of new PowerPoint Presentations in different languages customized to each acquirer’s identified industry, within each of the 12 industries. A Presentation per industry, presented to several potential acquirers within each industry.

Dr. Lev-Ari is bringing to the table a business candidate for an acquisition of the Intellectual property vast portfolio – three asset classes for common access by the entire BIOTECH Industry in Country x,y,z or the EU or another geography. The leading Global Conference Organizers for Global audiences in Biotech would benefit from IP Class III, and make it a product they currently do not have. Dr. Lev-Ari is interested in finding half a dozen appropriate potential acquirers, preferably in several geographies, who would champion the technology, the infrastructure, and the contents in Health care to continue this amazing series of accomplishments in three Industries:

Pharmaceutical (BioMed eBooks),

Media (e-Proceedings) and

electronic Scientific Publishing (Journal).

UPDATED on 2/10/2019 Leaders in Pharmaceutical Business Intelligence (LPBI) Group is an electronic scientific publishing venture that has developed platform architecture methodologies and business models of intellectual property development via scientific content creation by curation. These aspects of our intellectual property assist the e-Scientific Publishing Industry and scientific information users to mitigate the information explosion of scientific articles in the Life Sciences and Medicine and their inevitable immediate obsolescence. The work produced by LPBI Group is a team effort within the key domains of BioMed, BioTech, Pharmaco-therapy, MedTech, Health Care and the Life Sciences-Medicine connection. Our system technologies, which include platforms, methodologies and models, also include development of significant content materials. Additionally, this work can be replicated in many fields, i.e., Legal, Economics, Finance, International Relations, as examples of disciplines. It should be noted that all of LPBI’s material could, in principle, be translated into other languages. All members of our team have at least 10 years of experience in the life sciences area and have been trained to master the methodology of scientific curation used in our articles, in turn, if selected by experienced editors, these articles are targeted for inclusion in our books. The members of the team include senior MDs, MD/PhDs, FACC, FCAP, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes. Highly qualified content consultants are involved in each of the five e-series (senior MDs, MD/PhDs, and Professors) are engaged in the production of our curations. The topics for article curations and for the contents of the books we have created are carefully edited; I am the editor-in-chief and lead this multidisciplinary content compilation using my diverse areas of technical training and experience. Our intellectual property “IP” consists of three classes of assets as described in detail within live links in the below, listed article.

First, the Journal, an ongoing journal of curated, current biomedical research;
Second, the books, a collection of 16 volumes of e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomics, Cancer, Immunology and Precision Medicine; and
Third, real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in One-click operation.

These three IP asset classes are described in details with live links in eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/ LPBI’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. We have shown that synergy among experts, authors and writers yields outstanding collaborations in producing our curations. There are many post-doctoral individuals in biotech industries and academia who can serve as experts, authors and writers in continuing LPBI’s operations, following appropriate onboarding. The link, above is a summary of six demonstrations that justify these claims. The list of six points is followed by an extensive description of these valuable attributes of LPBI IP. The table for POINT #4 presents a concise summary of the functions and forms of LPBI IP three asset classes. UPDATED on 12/4/2018

2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets

LPBI Group Vision

UPDATED on 4/2/2018

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

UPDATED on 2/21/2016

We are in the Professional Services Sector: e-Scientific Information Creation and Intellectual Property Assets Management:

Subsidiary #1: electronic Scientific Media or Scientific Digital Media – LPBI

Journal,
BioMed eSeries,
Real Time Conference Press,
Audio-Podcast Series in Medicine

Subsidiary #1, LPBI, our Scientific Digital Media, is been managed to Plan for completion of milestones on 12/2016 – when it will be a candidate for M&A into the electronic Scientific Publishing Industry: Medical Publishers’ Directory – 171 publishing companies that publish Medical books, e-books, magazines. [ Page 1 of 18 ]

http://www.publishersglobal.com/directory/subject/medical-publishers/

Subsidiary #4: We are intermediaries for Commercialization, Licensing, Sales Outright of US Patents, representing Two inventors in Medical Devices

We are in 3D BioPrinting R&D & Drug Discovery R&D:

Subsidiary #3: R&D in 3D BioPrinting – FUNDING needs: $20Million [If VAR considered: $40Million]

Subsidiary #5: R&D in Drug Discovery – FUNDING needs: $20Million

We are in the Financial Transaction Sector

(No Securities Traded):

Subsidiary #2: Deals, Funding and Partnerships

MEDICAL DEVICES

Representation of Alpha Szensors, Inc. – Programmable sensors nanocarbon tubed for FUNDING – $XMillion for Manufacturing
Representation of ValveCure – Mitral Valve Repair Probe for M&A – $XMillion Sales
Representation of Telerescue – individualized portable Defibrilator for aFIB and CHF Patients for FUNDING – $XMillion

PLATFORM – Pharmaceutical KnowledgeBase – Global Relational DB of Oncology Drugs and Clinical Trial – the only one in existence for M&A or Unencumbered Sales of Assets – Quote available

Representation of New Medicine Inc.

INVENTIONS IN BIOLOGICS

Representation of BioTerm Therapeutics – Two Drug Devices Colagenease infusion – OBGYN Drug Injection and Syringe apparatus for FUNDING $XMillion each one
Representation of SBH Sciences, Inc. for FUNDING $X to $2XMillion – Brain Tumor drug
Representation of Woodlands Pharmaceutics for FUNDING $X to $2XMillion – Liver Fibrosis Drug

Drug Screening Phase to identify IF GDE will represent the following IP:

1. Small Molecules: Inventions of Professor Yedgar, HUJI, Licensable from Yissum, Tech Transfer HUJI

2. Biologics: Inventions of Professor Tirosh, HUJI, Licensable from Yissum, Tech Transfer HUJI – Yossi’s Company

3. Technion Tech Transfer: T-cube – Initiation of Relations by GDE – PENDING

4. Weizmann Institute Tech Transfer: YEDA – Initiation of Relations by GDE – PENDING

Material below that point is OUTDATED

This section is under construction

Our Open Access Online Journal

http://www.pharmaceuticalIntelligence.com is a scientific, medical and business, multi-expert authoring environment for information syndication in several domains of Life Sciences, Medicine, Pharmaceutical and Healthcare Industries, BioMedicine, Medical Technologies & Devices. Scientific critical interpretations and original articles are written by PhDs, MDs, MD/PhDs, PharmDs, Technical MBAs as Experts, Authors, Writers (EAWs) on an Equity Sharing basis.

Journal Content Descriptors on 2/18/2016

Date | Views to Date |# of articles |NIH Clicks |Nature Clicks

02/18/2016

886,454

4,162

2,911

1,813

Our Competencies

Deals, Partnerships and Funding for Early Stage Biologics and Medical Devices Start Ups

1. Early Stage Finance for Biologics and Medical Devices Start ups http://pharmaceuticalintelligence.com/joint-ventures/ 2. Medical 3D Printing and BioMaterials Process Control http://pharmaceuticalintelligence.com/medical-3d-printing/

Scientific Curations in Medicine and Life Sciences

http://www.pharmaceuticalIntelligence.com

HealthCare Investor’s Corner

http://pharmaceuticalintelligence.com/options/

BioMed e-Series of e-Books

http://pharmaceuticalintelligence.com/biomed-e-books/

Scientific Delegations of US Patent Holders

http://pharmaceuticalintelligence.com/options/scientific-delegation/

Real Time Coverage of Scientific and Biotech Conferences

http://pharmaceuticalintelligence.com/press-coverage/

MultiMedia Presence

Twitter.com: http://twitter.com/pharma_BI

@pharma_BI

FaceBook Page

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

Launchers of a Professional Group on LinkedIn

http://www.linkedin.com/groups?gid=4346921&trk=hb_side_g

Company Page on LinkedIn

https://www.linkedin.com/company/9325543?trk=vsrp_companies_res_name&trkInfo=VSRPsearchId%3A875971435604472931%2CVSRPtargetId%3A9325543%2CVSRPcmpt%3Aprimary

e-Book Titles by LPBI

For more information on Real-Time Conference Coverage and a full listing of Conferences Covered by LPBI please go to:

http://pharmaceuticalintelligence.com/press-coverage/

Leaders in Pharmaceutical Business Intelligence is a Holding Company of Six Ventures:

Venture Overview Updated in New Company Page on LinkedIn: Leaders in Pharmaceutical Business Intelligence – 3/7/2015 http://pharmaceuticalintelligence.com/2015/03/07/venture-overview-updated-on-new-company-page-on-linkedin-leaders-in-pharmaceutical-business-intelligence/

VENTURE #1:

e-Publishing: Medicine, HealthCare, Life Sciences, BioMed, Pharmaceutical– Open Access Online Scientific Journal http://pharmaceuticalintelligence.com

VENTURE #2:

BioMedical e-Books e-Series: Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine http://pharmaceuticalintelligence.com/biomed-e-books/

2013 e-Book on Amazon.com

Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013

http://www.amazon.com/dp/B00DINFFYC

2015 e-Book on Amazon.com

1. Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015

http://www.amazon.com/dp/B012BB0ZF0 2. Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015 http://www.amazon.com/dp/B013RVYR2K

3. Genomics Volume One

4. Physiology, Genomics and Pharmaceutical

5. Cardiovascular, Volume Two: Co-Curation, Methodology

6. Cardiovascular Diseases, Volume Three: Etiology, Genetics and Genomics

7. Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine

8. Cancer Volume Two: Immunotherapy, Nanotechnology in drug delivery

2016 we need to FIND Editors for Two e-Books

– Genomics Volume Two on NGS – Dr. Williams and another Editor

– Patient Voice on Invasive Procedures – New Editor

2016, We will continue with

– Aviva will work with Larry on CVD 5: Pharmacology-Therapy,

– With Adam and Dr. Pearlman, on CVD 6: Cardiac Surgery and Interventional

– With Adam and Dr. Pearlman, on CVD 7: CV Imaging

– Dr. Pearlman alone:

Three CVD Hardcopy Volumes, 1-Etiology, 2-Diagnostics, 3-Therapies

VENTURE #3:

International Scientific Delegations http://pharmaceuticalintelligence.com/scientific-delegation

VENTURE #4:

Funding, Deals & Partnerships http://pharmaceuticalintelligence.com/joint-ventures/

Business Development Plan for LPBI

– investors in Shanghai, China for funding Biologics and Medical Devices (Wilferd van Opstal)

– investors in Switzerland to find an e-Publisher to buy the Journal and the e-Books (Gerard Loiseau)

– a 3D Printing Swiss company – RegenHU — to establish Partnerships with MIT, GE, J&J [Adam on P&G]

– Adam drafts Patents with Bill Zurn on implantable Cardiovascular device – I am discussing Zurn’s IP with investors in Shanghai and NYC

– I work with investors in NYC (Nicholas Hall, Private Wealth Management, Maxim Group LLC) on Deals, Funding and Partnerships

VENTURE #5:

IP Invented HERE!

VENTURE # 6:

Real Time PRESS Coverage International Biotech Conferences http://pharmaceuticalintelligence.com/press-coverage/

Funding, Deals & Partnerships

Team members

Our Growth Needs: Leaders in Pharmaceutical Business Intelligence

Our Business Portfolio

VENTURE #1:

e-Publishing: Medicine, HealthCare, Life Sciences, BioMed, Pharmaceutical

Open Access Online Scientific Journal

11/19/2014 – PRESS RELEASE — Over 500,000 Unique Site Visits reached by PharmaceuticalIntelligence.com Reported today by Leaders in Pharmaceutical Business Intelligence (LPBI) http://pharmaceuticalintelligence.com/2014/11/19/over-500000-unique-site-visits-reached-by-pharmaceuticalintelligence-con-reported-today-by-leaders-in-pharmaceutical-business-intelligence-lbpi/ http://pharmaceuticalintelligence.com

Scoop.it!.com

VENTURE #2:

1. BioMedical e-Books e-Series: Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

http://pharmaceuticalintelligence.com/biomed-e-books/

2. on Amazon’s Kindle e-Books List since 6/2013

Perspectives on Nitric Oxide in Disease Mechanisms

3. Plans for Volume 1,2,3 – Hardcover

Cardiovascular Diseases: Causes, Risks and Management – Volume 1,2,3 – Hardcover

4. Schedule Plan for e-Publishing on Amazon.com

Publishing on Amazon Kindle – SIX Volumes in 2015:

1. Metabolomics, Volume One 2. Genomics, Volume One 3. Cancer Volume One 4. Cardiovascular – Volume 2 5. Cardiovascular – Volume 3 6. Cardiovascular – Volume 4

Publishing on Amazon Kindle – Four Volumes in 2016:

1. Physiology, PharmacoTherapy and Genomics: The Patient-centered Medicine Perspective 2. Cancer, Volume Two 3. Cardiovascular – Volume 5 4. Cardiovascular – Volume 6

VENTURE #3:

International Scientific Delegations http://pharmaceuticalintelligence.com/scientific-delegation/

Shanghai, May 2015
Barcelona, Spain, November 2015
Amsterdam, May 2016
Geneva, November 2016

VENTURE #4:

Funding, Deals & Partnerships

http://pharmaceuticalintelligence.com/joint-ventures/

VENTURE #5:

IP Invented HERE!

1. Development of a NEW Nitric Oxide monitor to Alpha Szenszor Inc. sensor portfolio. A concept for a low cost POC e-nose, capable of real time ppb detection of Cancer The Cancer Team at Leaders in Pharmaceutical Business Intelligence under the leadership of Dr. Williams 2. Development of a NEW Nitric Oxide monitor to Alpha Szenszor Inc. sensor portfolio. A concept for Inhaled Nitric Oxide for the Adult HomeCare Market – IP by Dr. Pearlman and Dr. A. Lev-Ari a. iknow iNO is i-kNOw – Inhaled Nitric Oxide for the HomeCare Market http://pharmaceuticalintelligence.com/2013/10/16/iknow-ino-is-i-know-inhaled-nitric-oxide-for-the-homecare-market/ b. electronic Book on Nitric Oxide by Nitric Oxide Team @ Leaders in Pharmaceutical Business Intelligence (LPBI) Perspectives on Nitric Oxide in Disease Mechanisms http://www.amazon.com/dp/B00DINFFYC c. The rationale and use of inhaled NO in Pulmonary Artery Hypertension and Right Sided Heart Failure Larry H. Bernstein 8/20/2012 d. Inhaled Nitric Oxide in Adults: Clinical Trials and Meta Analysis Studies – Recent Findings Aviva Lev-Ari, PhD, RN, 6/2/2013 e. Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care Aviva Lev-Ari, PhD, RN, 6/3/2013 3. Cancer Genomics for NEW product development in diagnosis and treatment of Cancer Patients using sensory technology with applications for Radiation Therapy – The Cancer Team at Leaders in Pharmaceutical Business Intelligence under leadership of Dr. Larry H Bernstein, MD, FCAP 4. Developing Mitral Valve Disease: MRI Methods and Devices for Percutaneous Mitral Valve Replacement and Mitral Valve Repair Augmentation of Patented Technology using RF – Dr. Pearlman’s IP Non-Hardware Mitral Annuloplasty – Dr. Justin D. Pearlman http://pharmaceuticalintelligence.com/joint-ventures/valvecure-llc/non-hardware-mitral-annuloplasty-dr-justin-d-pearlman/ 5. Novel Technology using MRI for Vascular Lesions, Tumors, Hyperactive Glands and non-Surgical Cosmetic Reconstruction – Dr. Pearlman’s IP http://pharmaceutica lintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/httppharmaceuticalintelligence-combiomed-e-bookscardiovascular-diseases-causes-risks-and-management/cvd-business-affairs/mitral-valve-disease-mri-methods-and-devices/

VENTURE # 6:

PRESS Coverage of Conferences

http://pharmaceuticalintelligence.com/press-coverage/

This page has the following sub pages.

16 Comments »

16 Responses

on April 15, 2013 at 4:10 PM | Reply We celebrate 800 articles, 4040 tags, 158,147 views, first article 4/30/2012 – Open Access Online Scientific Journal | Pharmaceutical Intelligence

I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette

Loading...
on August 8, 2013 at 2:44 PM | Reply Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation | Pharmaceutical Intelligence

I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette

Loading...
on September 15, 2014 at 4:19 AM | Reply Lens-Pechakova Lilia

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on September 15, 2014 at 7:08 AM | Reply 2012pharmaceutical

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on July 23, 2020 at 11:26 AM | Reply sjwilliamspa

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on July 23, 2020 at 11:55 AM | Reply sjwilliamspa

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on July 23, 2020 at 2:08 PM | Reply 2012pharmaceutical

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on August 12, 2020 at 3:41 AM | Reply Roni Roby

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on September 2, 2020 at 5:23 PM | Reply 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on October 23, 2020 at 2:51 PM | Reply Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on November 16, 2020 at 4:42 PM | Reply Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on January 1, 2021 at 3:54 AM | Reply Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management and New Technical Opportunities | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on January 9, 2021 at 8:07 PM | Reply e-Voices Podcasting by LPBI: Celebrating Podcast #3 in an Audio Library on leading Scientists and Key Opinion Leaders in Biological Sciences | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on January 30, 2021 at 5:39 PM | Reply One Possible Strategy for an Acquisition is via a SPAC | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on March 2, 2021 at 12:36 AM | Reply 2.0 LPBI is a Very Unique Organization | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...
on September 14, 2021 at 9:59 PM | Reply NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...